<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="psp413315" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">CPT Pharmacometrics Syst Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">2038</journal-id><journal-id journal-id-type="pmc-domain">cptpsp</journal-id><journal-id journal-id-type="publisher-id">PSP4</journal-id><journal-title-group><journal-title>CPT: Pharmacometrics &amp; Systems Pharmacology</journal-title></journal-title-group><issn pub-type="epub">2163-8306</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12001276</article-id><article-id pub-id-type="pmcid-ver">PMC12001276.1</article-id><article-id pub-id-type="pmcaid">12001276</article-id><article-id pub-id-type="pmcaiid">12001276</article-id><article-id pub-id-type="pmid">39959991</article-id><article-id pub-id-type="doi">10.1002/psp4.13315</article-id><article-id pub-id-type="publisher-id">PSP413315</article-id><article-id pub-id-type="other">PSP-2024-0249</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research</subject><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></subj-group></article-categories><title-group><article-title>Enhanced Sensitivity to Tramadol in Diabetic Neuropathic Pain Compared to Nerve Compression Neuropathies: A Population <styled-content style="fixed-case" toggle="no">PK</styled-content>/<styled-content style="fixed-case" toggle="no">PD</styled-content> Model Analysis</article-title></title-group><contrib-group><contrib id="psp413315-cr-0001" contrib-type="author"><name name-style="western"><surname>Chun</surname><given-names initials="D">Dain</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-3309-7883</contrib-id><xref rid="psp413315-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413315-cr-0002" contrib-type="author"><name name-style="western"><surname>Mehta</surname><given-names initials="P">Parsshava</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3435-9372</contrib-id><xref rid="psp413315-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413315-cr-0003" contrib-type="author"><name name-style="western"><surname>Guzy</surname><given-names initials="S">Serge</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-6342-9611</contrib-id><xref rid="psp413315-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="psp413315-cr-0004" contrib-type="author"><name name-style="western"><surname>Cicali</surname><given-names initials="B">Brian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7932-8599</contrib-id><xref rid="psp413315-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="psp413315-cr-0005" contrib-type="author"><name name-style="western"><surname>Lauretti</surname><given-names initials="GR">Gabriela R.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3691-8289</contrib-id><xref rid="psp413315-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="psp413315-cr-0006" contrib-type="author"><name name-style="western"><surname>Lanchote</surname><given-names initials="VL">Vera L.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0074-4953</contrib-id><xref rid="psp413315-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="psp413315-cr-0007" contrib-type="author" corresp="yes"><name name-style="western"><surname>Vozmediano</surname><given-names initials="V">Valvanera</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2636-1889</contrib-id><xref rid="psp413315-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>valva@ufl.edu</email><email>vvozmediano@ctifacts.com</email></address></contrib><contrib id="psp413315-cr-0008" contrib-type="author" corresp="yes"><name name-style="western"><surname>De Moraes</surname><given-names initials="N">Natalia</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4389-058X</contrib-id><xref rid="psp413315-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>nataliademoraes@ufl.edu</email></address></contrib></contrib-group><aff id="psp413315-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>University of Florida College of Pharmacy</institution>
<city>Orlando</city>
<named-content content-type="country-part">Florida</named-content>
<country country="US">USA</country>
</aff><aff id="psp413315-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Pop&#8208;Pharm Pharmacometrics Service</institution>
<city>Albany</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="psp413315-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">School of Medicine of Ribeirao Preto</named-content>
<institution>University of Sao Paulo</institution>
<city>Sao Paulo</city>
<country country="BR">Brazil</country>
</aff><aff id="psp413315-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">School of Pharmaceutical Sciences of Ribeirao Preto</named-content>
<institution>University of Sao Paulo</institution>
<city>Sao Paulo</city>
<country country="BR">Brazil</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence:</bold><break/>
Valvanera Vozmediano (<email>valva@ufl.edu</email>; <email>vvozmediano@ctifacts.com</email>)<break/>
Natalia De Moraes (<email>nataliademoraes@ufl.edu</email>)<break/></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>14</volume><issue seq="160">4</issue><issue-id pub-id-type="pmc-issue-id">486726</issue-id><issue-id pub-id-type="doi">10.1002/psp4.v14.4</issue-id><fpage>781</fpage><lpage>795</lpage><history><date date-type="rev-recd"><day>23</day><month>12</month><year>2024</year></date><date date-type="received"><day>16</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>02</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>17</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-17 10:26:06.673"><day>17</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2025 The Author(s). <italic toggle="yes">CPT: Pharmacometrics &amp; Systems Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#8208;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PSP4-14-781.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PSP4-14-781.pdf"/><abstract><title>ABSTRACT</title><p>Neuropathic pain, often associated with diabetic neuropathy or nerve compression injuries, arises from damage or dysfunction in the somatosensory nervous system. Tramadol, frequently prescribed for this pain, has its fraction unbound and that of its active metabolite (M1) significantly altered by diabetes. Yet, dosing adjustments for diabetic neuropathic pain remain underexplored. This study developed a comprehensive population pharmacokinetics/pharmacodynamics (PK/PD) model for tramadol and its major metabolites, focusing on diabetes's impact on PK and PK&#8208;PD relationship to identify optimal dosing regimens. Data from patients with chronic neuropathic pain on oral tramadol were used to develop enantiomer&#8208;specific population models, considering both total and unbound concentrations. Tramadol's PK was best described by a two&#8208;compartment model with Weibull absorption and linear elimination and a one&#8208;compartment model with enterohepatic circulation and first&#8208;pass metabolism for the active M1. Simulations showed higher unbound fractions of the active M1 in patients with type 1 and type 2 diabetes. Despite a 67% and 14% reduction in the AUC of total (<italic toggle="no">1R,2R</italic>)&#8208;M1 in patients with type 1 and type 2 diabetes, respectively, the AUC of unbound (<italic toggle="no">1R,2R</italic>)&#8208;M1 remained consistent. The unbound concentration of the active M1 required to achieve 50% of the maximum pain reduction (IC<sub>50</sub>) was lower in patients with diabetes, indicating increased sensitivity to the drug. This model&#8208;based approach provides valuable dosing guidance, suggesting once&#8208;daily dosing treatments in patients with diabetes and twice&#8208;daily dosing for patients with neuropathic pain secondary to nerve compression mechanisms.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="psp413315-kwd-0001">diabetes</kwd><kwd id="psp413315-kwd-0002">fraction unbound</kwd><kwd id="psp413315-kwd-0003">neuropathic pain</kwd><kwd id="psp413315-kwd-0004">PK/PD modeling</kwd><kwd id="psp413315-kwd-0005">tramadol enantiomers</kwd></kwd-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="15"/><word-count count="8900"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:16.04.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="psp413315-ntgp-0001"><fn fn-type="funding" id="psp413315-note-0001"><p>
<bold>Funding:</bold> The clinical study was funded by Financiadora de Estudos e Projetos (FINEP, Grant 01.05.0948.00) and Funda&#231;&#227;o de Apoio ao Ensino e Assist&#234;ncia do HCFMRP&#8208;USP (FAEPA). The data analysis and preparation of this article were performed independently of this grant.</p></fn></fn-group></notes></front><body id="psp413315-body-0001"><p>
<boxed-text position="anchor" content-type="box" id="psp413315-blkfxd-0001" orientation="portrait"><caption><title>Summary</title></caption><p>
<list list-type="bullet" id="psp413315-list-0001"><list-item id="psp413315-li-0001"><p>What is the current knowledge on the topic?
<list list-type="simple" id="psp413315-list-0002"><list-item id="psp413315-li-0002"><label>&#9675;</label><p>Neuropathic pain originates from lesions or dysfunction in the somatosensory nervous system due to various conditions, including diabetic neuropathy or nerve compression mechanisms.</p></list-item><list-item id="psp413315-li-0003"><label>&#9675;</label><p>Despite the different pathophysiology associated with those conditions, dose recommendations do not differentiate based on the cause of neuropathic pain.</p></list-item></list>
</p></list-item><list-item id="psp413315-li-0004"><p>What question did this study address?
<list list-type="simple" id="psp413315-list-0003"><list-item id="psp413315-li-0005"><label>&#9675;</label><p>The present study aimed to characterize the effect of diabetes on tramadol pharmacokinetics and pharmacodynamics using a population approach, providing guidance for selecting effective doses for diabetic neuropathic pain.</p></list-item></list>
</p></list-item><list-item id="psp413315-li-0006"><p>What does this study add to our knowledge?
<list list-type="simple" id="psp413315-list-0004"><list-item id="psp413315-li-0007"><label>&#9675;</label><p>This study is the first comprehensive exploration of pharmacokinetics and pharmacodynamics of both unbound and total tramadol, as well as its active metabolite, O&#8208;desmethyl&#8208;tramadol, in adult individuals with neuropathic pain, including those with or without diabetes.</p></list-item><list-item id="psp413315-li-0008"><label>&#9675;</label><p>The study highlights the impact of diabetes on tramadol's pharmacokinetics and pharmacodynamics, with diabetic patients exhibiting higher sensitivity to the drug.</p></list-item></list>
</p></list-item><list-item id="psp413315-li-0009"><p>How might this change drug discovery, development, and/or therapeutics?
<list list-type="simple" id="psp413315-list-0005"><list-item id="psp413315-li-0010"><label>&#9675;</label><p>Understanding the pharmacokinetics and pharmacodynamics of tramadol can guide clinical decision&#8208;making for optimizing tramadol dose to different neuropathic pain conditions.</p></list-item><list-item id="psp413315-li-0011"><label>&#9675;</label><p>These recommendations aim to enhance clinical practice and optimize the management of diabetic neuropathic pain.</p></list-item></list>
</p></list-item></list>
</p></boxed-text>
</p><sec id="psp413315-sec-0003"><label>1</label><title>Introduction</title><p>Neuropathic pain arises from lesions or dysfunction in the somatosensory nervous system. Various conditions are associated with the onset of neuropathic pain, including metabolic disorders such as diabetic neuropathy, viral infections such as human immunodeficiency virus (HIV), leprosy, or post&#8208;herpetic neuralgia, nerve compression damages (such as spinal cord injury, disc herniation, or amputation) as well as autoimmune disorders and inflammatory disorders. While some individuals experience mild symptoms, others suffer from incapacitating pain. Managing neuropathic pain often requires pain medications for effective relief. The pharmacological therapy for neuropathic pain includes gabapentinoids (i.e., gabapentin and pregabalin), tricyclic antidepressants, serotonin&#8208;norepinephrine reuptake inhibitors, and opioids such as tramadol and tapentadol [<xref rid="psp413315-bib-0001" ref-type="bibr">1</xref>, <xref rid="psp413315-bib-0002" ref-type="bibr">2</xref>, <xref rid="psp413315-bib-0003" ref-type="bibr">3</xref>]. Tramadol has demonstrated efficacy in reducing pain in diabetic peripheral neuropathy [<xref rid="psp413315-bib-0004" ref-type="bibr">4</xref>, <xref rid="psp413315-bib-0005" ref-type="bibr">5</xref>]. However, its use can be limited by side effects such as nausea, constipation, and vomiting. While tramadol is typically recommended as a second&#8208;line treatment, it may be considered first&#8208;line in patients with acute pain exacerbations [<xref rid="psp413315-bib-0004" ref-type="bibr">4</xref>]. Although dose recommendations typically do not differentiate based on the cause of neuropathic pain [<xref rid="psp413315-bib-0001" ref-type="bibr">1</xref>], the underlying condition can potentially affect drug exposure or the exposure&#8211;response relationship.</p><p>Tramadol, a centrally acting analgesic, is commonly prescribed for the treatment of neuropathic pain due to its favorable efficacy and safety profile&#160;[<xref rid="psp413315-bib-0002" ref-type="bibr">2</xref>, <xref rid="psp413315-bib-0003" ref-type="bibr">3</xref>]. It is available as a racemic mixture of <italic toggle="yes">(1R,2R)</italic>&#8208;tramadol and <italic toggle="yes">(1S,2S)</italic>&#8208;tramadol and effectively relieves moderate to severe pain through dual mechanisms: modulation of pain signal transmission via the &#956;&#8208;opioid receptor and weak inhibition of norepinephrine and serotonin reuptake [<xref rid="psp413315-bib-0006" ref-type="bibr">6</xref>, <xref rid="psp413315-bib-0007" ref-type="bibr">7</xref>]. Tramadol undergoes hepatic metabolism via CYP2D6, yielding O&#8208;desmethyltramadol (M1), and via CYP3A4 and CYP2B6, yielding N&#8208;desmethyltramadol (M2). Among its metabolites, M1 acts as a &#956;&#8208;opioid receptor agonist. Notably, <italic toggle="yes">(1R,2R)</italic>&#8208;M1 exhibits the highest &#956;&#8208;opioid receptor affinity, which is primarily responsible for its analgesic effects [<xref rid="psp413315-bib-0006" ref-type="bibr">6</xref>, <xref rid="psp413315-bib-0008" ref-type="bibr">8</xref>]. Its binding affinity to the &#956;&#8208;opioid receptor (Ki&#8201;=&#8201;3.4&#8201;nM) is significantly higher compared to that of racemic&#8208;tramadol (Ki&#8201;=&#8201;2.4&#8201;&#956;M) and to <italic toggle="yes">(1S,2S)</italic>&#8208;M1 (Ki&#8201;=&#8201;240&#8201;nM) [<xref rid="psp413315-bib-0006" ref-type="bibr">6</xref>, <xref rid="psp413315-bib-0007" ref-type="bibr">7</xref>, <xref rid="psp413315-bib-0008" ref-type="bibr">8</xref>]. In fact, the pupillary response was significantly increased in CYP2D6 normal metabolizers compared to poor metabolizers, underscoring the critical role of CYP2D6 metabolism in tramadol's therapeutic efficacy [<xref rid="psp413315-bib-0009" ref-type="bibr">9</xref>]. Additionally, both O&#8208; and N&#8208;demethylation of tramadol exhibit enantioselectivity [<xref rid="psp413315-bib-0006" ref-type="bibr">6</xref>]. Plasma concentrations at steady state for tramadol and M1 are typically reached within 2&#8201;days [<xref rid="psp413315-bib-0010" ref-type="bibr">10</xref>, <xref rid="psp413315-bib-0011" ref-type="bibr">11</xref>].</p><p>Our previous research has demonstrated that diabetes significantly alters the fraction unbound (<mml:math id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi></mml:mrow></mml:mrow></mml:math>) and exposure to the active total <italic toggle="yes">(1R,2R)</italic>&#8208;M1 [<xref rid="psp413315-bib-0012" ref-type="bibr">12</xref>]. However, it remains unclear whether diabetes could potentially change the pharmacokinetic/pharmacodynamic (PK/PD) relationship for tramadol in neuropathic pain. The current recommended dosage for the effective management of pain related to diabetic neuropathy stands at an average of 210&#8201;mg per day [<xref rid="psp413315-bib-0013" ref-type="bibr">13</xref>, <xref rid="psp413315-bib-0014" ref-type="bibr">14</xref>]. Clinical practice guidelines recommend initial daily doses of 50&#8201;mg, with a gradual titration using 50&#8201;mg dose increments, with a maximum daily dosage of 400&#8201;mg [<xref rid="psp413315-bib-0002" ref-type="bibr">2</xref>]. However, the evidence substantiating the dose recommendation of tramadol for managing diabetic neuropathic pain is limited, and there is a lack of PK/PD assessment for this indication. Given the escalating annual incidence of diabetes [<xref rid="psp413315-bib-0015" ref-type="bibr">15</xref>], it is essential to understand the impact of diabetes on the PK and PD of tramadol. Utilizing extensive clinical PK and PD data in patients with neuropathic pain secondary to diabetes or nerve compression mechanisms, our aim is to develop a population PK/PD model to characterize the exposure of tramadol and its major metabolites. We seek to assess whether diabetes changes the PK/PD relationship for tramadol. Furthermore, should a need for dose adjustment arise, our objective is to optimize tramadol dosing regimens tailored to diabetic neuropathic pain and neuropathic pain secondary to nerve compression mechanisms.</p></sec><sec sec-type="methods" id="psp413315-sec-0004"><label>2</label><title>Methods</title><sec id="psp413315-sec-0005"><label>2.1</label><title>Clinical Study</title><p>This study is a secondary analysis of clinical data obtained in patients with chronic neuropathic pain for more than 3&#8201;months and pain scores rated above 40 out of 100 [<xref rid="psp413315-bib-0012" ref-type="bibr">12</xref>]. Written informed consent was obtained from each participant, and the study was approved by the local ethical institutional review board at the Hospital of the University of Sao Paulo, Brazil (1775/2008) and as exempt at the University of Florida (IRB202200717). In summary, all patients received a single oral dose of tramadol (100&#8201;mg, Tramal, Pfizer) after an 8&#8208;h fasting period, accompanied by 200&#8201;mL of water. A standard meal was provided to all patients only 2&#8201;h after drug administration to avoid a food effect. Blood samples were collected before and up to 24&#8201;h after drug administration to analyze plasma concentrations of tramadol and its primary metabolites, O&#8208;desmethyl tramadol, and N&#8208;desmethyl tramadol, using a validated LC&#8211;MS/MS method [<xref rid="psp413315-bib-0016" ref-type="bibr">16</xref>]. The analytical method discriminated enantiomers and was applied to analyze total and unbound plasma concentrations, with the latter determined following an ultrafiltration step. The linear ranges and the lower limits of quantification for the bioanalytical method are provided in Table&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S1</xref>, Supporting Information. Pain scores were evaluated at baseline and at the same sampling times as in the PK study using a visual analog scale (VAS) on a 100&#8201;mm line, where patients marked their pain level, with 0 indicating &#8220;no pain&#8221; and 100 indicating &#8220;worst possible pain&#8221; (Figure&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S3</xref>, Supporting Information). Blood samples were also collected for various laboratory tests, including fasting blood glucose (FBG) level, hemoglobin A1C (HbA1C), serum creatinine, serum urea, albumin, aspartate transaminase (AST), and alanine transaminase (ALT). The glomerular filtration rate (eGFR) was calculated based on the CKD&#8208;EPI Creatinine Equation (2021) [<xref rid="psp413315-bib-0017" ref-type="bibr">17</xref>]. Given the significance of the CYP2D6 enzyme in the formation of the active M1 metabolite, all patients underwent an assessment of the in&#160;vivo activity of CYP2D6 using metoprolol as a probe drug [<xref rid="psp413315-bib-0018" ref-type="bibr">18</xref>]. Following the administration of 100&#8201;mg of metoprolol (Lopressor, Novartis), urine samples were collected in the 0&#8211;8&#8201;h interval for the analysis of metoprolol and its metabolite &#945;&#8208;hydroxy metoprolol using a validated HPLC method with fluorescence detection [<xref rid="psp413315-bib-0019" ref-type="bibr">19</xref>]. The in&#160;vivo activity of CYP2D6 was expressed for each subject by the metabolic ratio of metoprolol/&#945;&#8208;hydroxy metoprolol (MR<sub>Met/OH&#8208;met</sub>) in 0&#8208;8&#8201;h urine samples [<xref rid="psp413315-bib-0016" ref-type="bibr">16</xref>].</p></sec><sec id="psp413315-sec-0006"><label>2.2</label><title>Pharmacokinetic Analysis</title><p>A population PK model was developed using unbound and total plasma concentrations of each tramadol enantiomer and its primary metabolites, M1 and M2 (Figures&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S1</xref> and <xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S2</xref>, Supporting Information). Non&#8208;linear mixed effect modeling using the First Order Conditional Estimation with Interaction (FOCE&#8208;I) algorithm was implemented using NONMEM version 7.4.4 (Icon Development Solutions, Ellicott City, MD) and R version 4.4.1. A sequential approach was adopted in the model development process, wherein the PK parameters were fixed to their individual post hoc estimates. This systematic method involved addressing tramadol first, followed by M1 and M2 for each respective enantiomer. Plasma concentration data were converted into molar units to accommodate parent&#8211;metabolite conversion. The molar mass used for this conversion were 263.37&#8201;g/mol for tramadol and 249.35&#8201;g/mol for both O&#8208;desmethyl&#8208;tramadol and N&#8208;desmethyl&#8208;tramadol [<xref rid="psp413315-bib-0020" ref-type="bibr">20</xref>, <xref rid="psp413315-bib-0021" ref-type="bibr">21</xref>, <xref rid="psp413315-bib-0022" ref-type="bibr">22</xref>].</p><p>A defining feature of the parent&#8211;metabolite model is its simultaneous modeling of both unbound and total drug concentrations (Equation&#160;<xref rid="psp413315-disp-0001" ref-type="disp-formula">1</xref>), enabling the estimation of the unbound fraction (<mml:math id="jats-math-2" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>u</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math>).<disp-formula id="psp413315-disp-0001"><label>(1)</label><mml:math id="jats-math-3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mtext>total</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mtext>unbound</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mtext>bound</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mtext>unbound</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>b</mml:mi></mml:msub><mml:mo>&#8729;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mtext>unbound</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-4" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mtext>total</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math> is the total drug concentration, <mml:math id="jats-math-5" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mtext>unbound</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math> is the unbound drug concentration, <mml:math id="jats-math-6" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mtext>bound</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math> is the protein&#8208;bound concentration, and <mml:math id="jats-math-7" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> is the binding proportionality constant (i.e., <mml:math id="jats-math-8" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mtext>bound</mml:mtext></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mtext>unbound</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math>). It was assumed that protein binding exhibited linearity at therapeutic drug concentrations in the absence of a saturable mechanism [<xref rid="psp413315-bib-0023" ref-type="bibr">23</xref>], as represented by Equations&#160;(<xref rid="psp413315-disp-0002" ref-type="disp-formula">2</xref>) and (<xref rid="psp413315-disp-0003" ref-type="disp-formula">3</xref>):<disp-formula id="psp413315-disp-0002"><label>(2)</label><mml:math id="jats-math-9" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>K</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413315-disp-0003"><label>(3)</label><mml:math id="jats-math-10" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mtext>total</mml:mtext></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>f</mml:mi><mml:mi>u</mml:mi></mml:msub></mml:mfrac><mml:mo>&#8729;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mtext>unbound</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>
<mml:math id="jats-math-11" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>b</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> was estimated in the model, allowing the <mml:math id="jats-math-12" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mi>u</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> to be constrained between 0 and 1. Various delayed absorption models were explored to capture the initial delay and the lag of the absorption rate of tramadol, including first&#8208;order input with or without a lag time and transit compartment model. To account for a time&#8208;dependent absorption rate constant [<mml:math id="jats-math-13" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math>] [<xref rid="psp413315-bib-0024" ref-type="bibr">24</xref>], a Weibull absorption which is a type of cumulative distribution function (cdf) was incorporated as follows (Equation&#160;<xref rid="psp413315-disp-0004" ref-type="disp-formula">4</xref>):<disp-formula id="psp413315-disp-0004"><label>(4)</label><mml:math id="jats-math-14" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mi>a</mml:mi></mml:msub><mml:mfenced close=")" open="("><mml:mi>t</mml:mi></mml:mfenced><mml:mo linebreak="goodbreak">=</mml:mo><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:mspace width="0.25em"/><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>&#947;</mml:mi><mml:mspace width="0.25em"/></mml:mrow><mml:mi>&#946;</mml:mi></mml:mfrac></mml:mfenced><mml:mi>&#945;</mml:mi></mml:msup></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mi>&#947;</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>&#945;</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-15" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#945;</mml:mi></mml:mrow></mml:mrow></mml:math> is a shape parameter, <mml:math id="jats-math-16" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:mrow></mml:math> is a scale parameter, and <mml:math id="jats-math-17" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#947;</mml:mi></mml:mrow></mml:mrow></mml:math> is a location parameter.</p><p>Two assumptions were made to address the identifiability issues associated with the metabolites. First, leveraging the data observed in rats [<xref rid="psp413315-bib-0025" ref-type="bibr">25</xref>], allometric weight scaling was applied to obtain the volume of distribution of M1 in humans. The allometric weight exponent was fixed to 1.<disp-formula id="psp413315-disp-0005"><mml:math id="jats-math-18" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mtext>human</mml:mtext></mml:mrow></mml:msub><mml:mi>F</mml:mi></mml:mfrac><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>rat</mml:mi></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:mspace width="0.25em"/><mml:msub><mml:mi mathvariant="italic">WT</mml:mi><mml:mtext>human</mml:mtext></mml:msub><mml:mspace width="0.25em"/></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">WT</mml:mi><mml:mi>rat</mml:mi></mml:msub><mml:mspace width="0.25em"/></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413315-disp-0006"><mml:math id="jats-math-19" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mtext>human</mml:mtext></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mtext>human</mml:mtext></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi><mml:mo>&#8729;</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi mathvariant="italic">fu</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-20" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mtext>human</mml:mtext></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math> is the typical apparent volume of distribution of total <italic toggle="yes">M</italic>1 in human, <mml:math id="jats-math-21" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi><mml:mo>,</mml:mo><mml:mtext>human</mml:mtext></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math> is the typical apparent unbound volume of distribution of <italic toggle="yes">M</italic>1 in human, <mml:math id="jats-math-22" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>rat</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is the volume of distribution of total <italic toggle="yes">M</italic>1 in rat, <mml:math id="jats-math-23" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">WT</mml:mi><mml:mtext>human</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math> is the average total body weight of human, and <mml:math id="jats-math-24" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">WT</mml:mi><mml:mi>rat</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> is the average total body weight of rat. The values used in the calculations were as follows: <mml:math id="jats-math-25" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>R</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>rat</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.1</mml:mn><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mi>L</mml:mi></mml:mfenced><mml:mo>,</mml:mo><mml:mspace width=".2pc"/><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>S</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:mi>rat</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.255</mml:mn><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mi>L</mml:mi></mml:mfenced><mml:mo>,</mml:mo><mml:mspace width=".2pc"/><mml:msub><mml:mi mathvariant="italic">WT</mml:mi><mml:mtext>human</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mn>72.2</mml:mn><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mi>kg</mml:mi></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-26" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi mathvariant="italic">WT</mml:mi><mml:mi>rat</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0.235</mml:mn><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mi>kg</mml:mi></mml:mfenced></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math>. Secondly, based on the published literature, it is known that an average of 30% of tramadol dose is eliminated by renal excretion as unchanged drug. Thus, the proportion of apparent unbound drug clearance from the central compartment of tramadol (<mml:math id="jats-math-27" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi><mml:mtext>other</mml:mtext><mml:mi>u</mml:mi><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>) was fixed to 0.3 [<xref rid="psp413315-bib-0026" ref-type="bibr">26</xref>, <xref rid="psp413315-bib-0027" ref-type="bibr">27</xref>].</p><p>Pharmacokinetic parameters associated with the random effect were assumed to be log&#8208;normally distributed. Ultimately, a pharmacokinetic parameter was defined as:<disp-formula id="psp413315-disp-0007"><mml:math id="jats-math-28" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8729;</mml:mo><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:msub><mml:mi>&#951;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-29" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> is the <italic toggle="yes">i</italic>th parameter for <mml:math id="jats-math-30" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mrow></mml:math> patient; <mml:math id="jats-math-31" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> is the population parameter estimate; and <mml:math id="jats-math-32" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#951;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> is the deviation from the population mean for <italic toggle="yes">i</italic>th parameter for <italic toggle="yes">j</italic> patient such that <mml:math id="jats-math-33" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#951;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mfenced close=")" open="(" separators=","><mml:mn>0</mml:mn><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfenced></mml:mrow></mml:mrow></mml:math>. Residual error was modeled using a proportional error applied to concentrations for tramadol, M1, and M2 enantiomers as defined below:<disp-formula id="psp413315-disp-0008"><mml:math id="jats-math-34" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>&#8729;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">+</mml:mo><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi><mml:mo>,</mml:mo><mml:mtext>prop</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-35" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-36" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>F</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> are the observed and model predicted concentrations, respectively,&#160;for subject <mml:math id="jats-math-37" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mrow></mml:math> and time <mml:math id="jats-math-38" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-39" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi><mml:mo>,</mml:mo><mml:mtext>prop</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> are the proportional residual errors for subject <italic toggle="yes">i</italic> and time <italic toggle="yes">j</italic> such that<disp-formula id="psp413315-disp-0088"><mml:math id="jats-math-40" display="block" overflow="scroll"><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi><mml:mo>,</mml:mo><mml:mtext>prop</mml:mtext></mml:mrow></mml:msub><mml:mo>&#8764;</mml:mo><mml:mi>N</mml:mi><mml:mfenced close=")" open="(" separators=","><mml:mn>0</mml:mn><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mtext>prop</mml:mtext><mml:mn>2</mml:mn></mml:msubsup></mml:mfenced><mml:mo>.</mml:mo></mml:math></disp-formula>
</p></sec><sec id="psp413315-sec-0007"><label>2.3</label><title>Pharmacodynamic Analysis</title><p>Pain score observations were recorded using a VAS within a range of 0&#8211;100&#8201;mm, where a score of 0 represented no pain and 100&#8201;mm indicated the worst pain. However, for analytical purposes and to facilitate constraints, we standardized the data to a range between 0 and 1. Given that <italic toggle="yes">(1R,2R)&#8208;</italic>M1 is the active metabolite, and efficacy is associated with the unbound drug concentrations at the site of action, we utilized the predicted unbound concentration of <italic toggle="yes">(1R,2R)&#8208;</italic>M1 to establish a relationship with the PD endpoint. The effectiveness variable, VAS pain score, was treated as a continuous variable. The concentration&#8211;effect relationship was described using an inhibitory <italic toggle="yes">E</italic>
<sub>max</sub> PD model with an effect compartment to account for delay, as follows (Equations&#160;<xref rid="psp413315-disp-0009" ref-type="disp-formula">5</xref> and <xref rid="psp413315-disp-0010" ref-type="disp-formula">6</xref>):<disp-formula id="psp413315-disp-0009"><label>(5)</label><mml:math id="jats-math-41" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mi>eff</mml:mi></mml:msub></mml:mrow><mml:mi mathvariant="italic">dt</mml:mi></mml:mfrac><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#8729;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
<disp-formula id="psp413315-disp-0010"><label>(6)</label><mml:math id="jats-math-42" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#8729;</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo linebreak="goodbreak">&#8722;</mml:mo><mml:mfrac><mml:mrow><mml:mspace width="0.25em"/><mml:mspace width="0.25em"/><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>max</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>&#8729;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">IC</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-43" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> represents the delay relative to the plasma concentration by a first&#8208;order rate constant, <mml:math id="jats-math-44" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> represents the predicted apparent unbound concentration of <italic toggle="yes">(1R,2R)&#8208;</italic>M1 in the <italic toggle="yes">i</italic>th subject at the <italic toggle="yes">j</italic>th time point, <mml:math id="jats-math-45" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mspace width="0.25em"/><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is the apparent unbound <italic toggle="yes">(1R,2R)&#8208;</italic>M1 concentration in the effect compartment in the <italic toggle="yes">i</italic>th subject at the <italic toggle="yes">j</italic>th time point, <mml:math id="jats-math-46" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> represents the baseline pain score value using VAS when no drug is present at time <mml:math id="jats-math-47" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math> for <mml:math id="jats-math-48" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mrow></mml:math> individual, <mml:math id="jats-math-49" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mrow><mml:mi>max</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is the maximum fraction of treatment effect of tramadol in <italic toggle="yes">i</italic>th subject, and <mml:math id="jats-math-50" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">IC</mml:mi><mml:mrow><mml:mn>50</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is the concentration (<mml:math id="jats-math-51" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi mathvariant="normal">L</mml:mi></mml:mrow></mml:mrow></mml:math>) at half of the maximal drug effect. Because both pain score observation and the individual prediction should be constrained between 0 and 1, a logit&#8208;transformation was applied to efficacy estimation as follows (Equation&#160;<xref rid="psp413315-disp-0011" ref-type="disp-formula">7</xref>):<disp-formula id="psp413315-disp-0011"><label>(7)</label><mml:math id="jats-math-52" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="italic">ln</mml:mi><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi><mml:mo mathvariant="italic">,</mml:mo><mml:mi>add</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="italic">ln</mml:mi><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi>&#955;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi><mml:mo mathvariant="italic">,</mml:mo><mml:mi>add</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>&#8804;</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>&#8804;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-53" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> represents the observed value for individual <mml:math id="jats-math-54" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mrow></mml:math> at time<mml:math id="jats-math-55" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mspace width="0.25em"/><mml:mi>j</mml:mi></mml:mrow></mml:mrow></mml:math>, and <mml:math id="jats-math-56" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#955;</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> represents the predicted efficacy for individual <italic toggle="yes">i</italic> at time <italic toggle="yes">j</italic>, and <mml:math id="jats-math-57" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi><mml:mo mathvariant="italic">,</mml:mo><mml:mi>add</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is the residual error such that <mml:math id="jats-math-58" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#949;</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mo>,</mml:mo><mml:mi>add</mml:mi></mml:mrow></mml:msub><mml:mo>&#8764;</mml:mo><mml:mi>N</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mn>0</mml:mn><mml:mo separator="true">,</mml:mo><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mi>add</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>. Additionally, considering that the estimations for <mml:math id="jats-math-59" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>max</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-60" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math> must fall within the range of 0 to 1, and recognizing that the predictions of these continuous parameters could potentially extend to infinity, a logit&#8208;transformation was applied to these parameters [<xref rid="psp413315-bib-0028" ref-type="bibr">28</xref>]. An additive IIV was used on the logit scale as follows (Equation&#160;<xref rid="psp413315-disp-0012" ref-type="disp-formula">8</xref>):<disp-formula id="psp413315-disp-0012"><label>(8)</label><mml:math id="jats-math-61" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="italic">ln</mml:mi><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="italic">tv&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi mathvariant="italic">tv&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mi>&#951;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mspace width="0.25em"/></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>exp</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mi mathvariant="italic">ln</mml:mi><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:msub><mml:mi mathvariant="italic">tv&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msub><mml:mi mathvariant="italic">tv&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>+</mml:mo><mml:msub><mml:mi>&#951;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo>&#8804;</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8804;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-62" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> represents the parameter <mml:math id="jats-math-63" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>max</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> or <mml:math id="jats-math-64" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math> for individual <mml:math id="jats-math-65" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-66" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">tv&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> was fixed effect (typical value of parameter) for individual <mml:math id="jats-math-67" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mrow></mml:math>, and <mml:math id="jats-math-68" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#951;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> is the deviation from the population mean for individual <mml:math id="jats-math-69" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mrow></mml:math> such that <mml:math id="jats-math-70" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#951;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mfenced close=")" open="(" separators=","><mml:mn>0</mml:mn><mml:msup><mml:mi>&#969;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mfenced></mml:mrow></mml:mrow></mml:math>.</p></sec><sec id="psp413315-sec-0008"><label>2.4</label><title>Covariate Analysis</title><p>Upon establishing a foundational parent&#8211;metabolite joint model, demographic and clinical variables were tested as potential covariates, including age, sex, body mass index (BMI), FBG level, HbA1C, serum creatinine, urea level, albumin, AST, ALT, CYP2D6 in&#160;vivo activity, CYP3A4 in&#160;vivo activity, and CYP2B6 genotype. All observations were complete, with no missing data for any covariates. After evaluating the additive linear model, the proportional linear model, and the power model, a power function was selected for continuous covariates, as represented by Equation&#160;(<xref rid="psp413315-disp-0013" ref-type="disp-formula">9</xref>):<disp-formula id="psp413315-disp-0013"><label>(9)</label><mml:math id="jats-math-71" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#952;</mml:mi><mml:mo linebreak="goodbreak">=</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mi mathvariant="italic">tv</mml:mi></mml:msub><mml:mo>&#8729;</mml:mo><mml:msup><mml:mfenced close=")" open="("><mml:mfrac><mml:mi mathvariant="italic">Cov</mml:mi><mml:mrow><mml:mspace width="0.25em"/><mml:msub><mml:mi mathvariant="italic">Cov</mml:mi><mml:mi>med</mml:mi></mml:msub><mml:mspace width="0.25em"/></mml:mrow></mml:mfrac></mml:mfenced><mml:mi>&#946;</mml:mi></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula>
</p><p>Here, <mml:math id="jats-math-72" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#952;</mml:mi></mml:mrow></mml:mrow></mml:math> represents the population parameter, <mml:math id="jats-math-73" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">Cov</mml:mi></mml:mrow></mml:mrow></mml:math> represents the covariate value, <mml:math id="jats-math-74" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi mathvariant="italic">tv</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> is the typical value with a standardized covariate value of <mml:math id="jats-math-75" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Cov</mml:mi><mml:mi>med</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math>, and <mml:math id="jats-math-76" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>&#946;</mml:mi></mml:mrow></mml:mrow></mml:math> is the power coefficient describing covariate parameter relationship. Standardized values of the covariates were the values regarded as reference in the general population. Reference values were median value 26.045 kg/m<sup>2</sup> for BMI and median value 0.610 for CYP2D6 in&#160;vivo activity.</p><p>For categorial variable diabetes, proportional linear model was used as represented by Equation&#160;(<xref rid="psp413315-disp-0014" ref-type="disp-formula">10</xref>):<disp-formula id="psp413315-disp-0014"><label>(10)</label><mml:math id="jats-math-77" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>&#946;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#8729;</mml:mo><mml:msub><mml:mi>&#952;</mml:mi><mml:mi mathvariant="italic">ref</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>T</mml:mi><mml:mn>1</mml:mn><mml:mi mathvariant="italic">DM</mml:mi><mml:mspace width="0.25em"/><mml:mtext>or</mml:mtext><mml:mspace width="0.25em"/><mml:mi>T</mml:mi><mml:mn>2</mml:mn><mml:mi mathvariant="italic">DM</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula>where <mml:math id="jats-math-78" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> represents the population parameter for patients with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), <mml:math id="jats-math-79" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#952;</mml:mi><mml:mi mathvariant="italic">ref</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> represents the population parameter for the reference group, patients without diabetes, and <mml:math id="jats-math-80" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>&#946;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math> represents the covariate effect coefficient.</p><p>Both visual and numerical methods were employed to screen significant covariates. Scatter plots were used to visualize the relationship between covariates and parameters for continuous variables, while box plots were used to compare these variables across groups. The &#8722;2 log&#8208;likelihood (&#8722;2LL) was computed to compare nested models. A <italic toggle="yes">p</italic>&#8208;value of less than 0.05 indicated statistical significance for the inclusion of covariates in the model. A univariate covariate and stepwise covariate analysis were tested. For the stepwise addition, a significance level of 0.05 was employed for forward selection, while a significance level of 0.01 was used for the backward deletion of covariates from the full final model.</p></sec><sec id="psp413315-sec-0009"><label>2.5</label><title>Model Evaluation</title><p>Model evaluation was conducted through various approaches to assess its suitability and performance. Goodness of fit (GOF) plots were used as an indicator of suitability, including the representation of model&#8208;based individual predictions and population predictions versus the observed concentration. Visual predictive check (VPC) was constructed using the 5th, 50th, and 95th percentiles of the observed data to evaluate the simulation prediction. In addition, a non&#8208;parametric bootstrap analysis of 500 simulations was conducted to verify parameter estimates [<xref rid="psp413315-bib-0023" ref-type="bibr">23</xref>, <xref rid="psp413315-bib-0028" ref-type="bibr">28</xref>].</p></sec><sec id="psp413315-sec-0010"><label>2.6</label><title>Simulation of Exposure and Response</title><p>Using the developed PK/PD model, simulations of exposure to tramadol and its main metabolites and pain scores were conducted for a comprehensive comparison across different groups based on significant covariates. Model simulations were performed using a virtual population of 500 subjects. Drug exposure was assessed using the area under the plasma concentration&#8211;time curve from 0 to 24&#8201;h (AUC<sub>0&#8208;24</sub>). Median values and 95% confidence intervals (95% CI) were calculated when comparing exposures. For the response simulation, pain scores were normalized by baseline following steady&#8208;state tramadol treatment. Additionally, simulations of different dosing scenarios were performed with escalating doses from 50&#8201;mg to the maximum daily dosage of 400&#8201;mg. The percentage of subjects experiencing substantial pain relief (&gt;&#8201;50% reduction from baseline pain score) and moderate pain relief (30%&#8211;50% reduction from baseline pain score) was recorded. Pain relief was assessed at the time of maximum pain attenuation following a single dose as well as at trough concentrations 72&#8201;h after multiple dose treatment to characterize the sustained pain relief effect [<xref rid="psp413315-bib-0029" ref-type="bibr">29</xref>, <xref rid="psp413315-bib-0030" ref-type="bibr">30</xref>, <xref rid="psp413315-bib-0031" ref-type="bibr">31</xref>]. This investigation aimed to explore optimal dosing regimens for tramadol across various patient populations. All simulations were conducted using R Studio and the rxode2 package.</p></sec></sec><sec sec-type="results" id="psp413315-sec-0011"><label>3</label><title>Results</title><sec id="psp413315-sec-0012"><label>3.1</label><title>Data</title><p>The dataset included 30 patients with 2145 observations of PK concentrations, encompassing total and unbound concentrations of tramadol, M1, and M2 enantiomers, and 27 patients with 402 observations of PD endpoints. The descriptive statistics of demographics and clinical characteristics are shown in Table&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S2</xref>. The cohort had an approximately equal distribution of men (<italic toggle="yes">n</italic>&#8201;=&#8201;14, 46.7%) and women (<italic toggle="yes">n</italic>&#8201;=&#8201;16, 53.3%), with an age range of 19 and 59&#8201;years and a BMI range of 17.2 and 38.9&#8201;kg/m<sup>2</sup>.</p></sec><sec id="psp413315-sec-0013"><label>3.2</label><title>Pharmacokinetic/Pharmacodynamic Analysis</title><p>The PK of both <italic toggle="yes">(1R,2R)&#8208;</italic> and <italic toggle="yes">(1S,2S)&#8208;</italic>tramadol were best described by a two&#8208;compartment model with Weibull absorption and linear elimination (Step 1, Figure&#160;<xref rid="psp413315-fig-0001" ref-type="fig">1</xref>; Table&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S3</xref>). A one&#8208;compartment model with linear formation and linear elimination characterized both unbound and total concentration data for <italic toggle="yes">(1R,2R)&#8208;</italic> and <italic toggle="yes">(1S,2S)&#8208;</italic>M1 (Table&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S4</xref>), with individual post hoc parameter estimates from Step 1. Furthermore, incorporating the first&#8208;pass metabolism improved the fit of the first&#8208;time point observation of the metabolite M1. While tramadol is known to undergo a 20%&#8211;30% first&#8208;pass effect [<xref rid="psp413315-bib-0010" ref-type="bibr">10</xref>], our model estimated the proportion of first&#8208;pass effect (<mml:math id="jats-math-81" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>fp</mml:mi></mml:mrow></mml:mrow></mml:math>) at 6% specifically for the M1 metabolite, suggesting that first&#8208;pass metabolism may generate other metabolites in addition to M1. To capture the multiple secondary peaks observed in the M1 plasma concentration profile (Figure&#160;<xref rid="psp413315-fig-0002" ref-type="fig">2</xref>), an enterohepatic circulation process was implemented in the M1 model by adding a bile compartment. The inclusion of enterohepatic circulation is attributed to the conjugation of M1 with glucuronic acid to form M1&#8208;glucuronides, which are excreted in bile and urine in rats [<xref rid="psp413315-bib-0032" ref-type="bibr">32</xref>]. Furthermore, exposure to the active M1 is significantly reduced in bile duct&#8208;ligated rats in a perfused rat liver model [<xref rid="psp413315-bib-0033" ref-type="bibr">33</xref>], suggesting that enterohepatic circulation plays a significant role in M1 exposure.</p><fig position="float" fig-type="FIGURE" id="psp413315-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Sequential population PK/PD model for total and unbound concentrations of (<italic toggle="yes">1R,2R</italic>)&#8208;tramadol and its metabolites (<italic toggle="yes">1R,2R</italic>)&#8208;O&#8208;desmethyltramadol (M1) and (<italic toggle="yes">1R,2R</italic>)&#8208;N&#8208;desmethyltramadol (M2) and (<italic toggle="yes">1S,2S</italic>)&#8208;tramadol and its metabolites (<italic toggle="yes">1S,2S</italic>)&#8208;O&#8208;desmethyltramadol (M1) and (<italic toggle="yes">1S,2S</italic>)&#8208;N&#8208;desmethyltramadol (M2). The PK model consists of a two&#8208;compartment model for unbound tramadol with a central compartment (apparent volume <mml:math id="jats-math-82" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>) and a peripheral compartment (<mml:math id="jats-math-83" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vp</mml:mi><mml:mrow><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>) with the Weibull absorption model [fraction (1&#8208;<mml:math id="jats-math-84" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fp</mml:mi></mml:mrow></mml:mrow></mml:math>) and time&#8208;dependent absorption rate constant (<mml:math id="jats-math-85" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">ka</mml:mi></mml:mrow></mml:mrow></mml:math>)]. Total and unbound plasma concentrations were simultaneous modeled to estimate the fraction unbound (<mml:math id="jats-math-86" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi></mml:mrow></mml:mrow></mml:math>) assuming that binding to plasma protein is linear. A one&#8208;compartment model was used to describe M1 total and unbound plasma concentrations (volumes <mml:math id="jats-math-87" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-88" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>). The M1 metabolite formation was modeled using the linear elimination from the parent compound [fraction of M1 creation (<mml:math id="jats-math-89" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fm</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math>) and formation clearance (<mml:math id="jats-math-90" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CLF</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi mathvariant="normal">F</mml:mi></mml:mrow></mml:mrow></mml:math>)] and the model accounted for first&#8208;pass metabolism [fraction (<mml:math id="jats-math-91" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fp</mml:mi></mml:mrow></mml:mrow></mml:math>) and rate constant <mml:math id="jats-math-92" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi>K</mml:mi><mml:mi>met</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>] and enterohepatic circulation [bile volume (<mml:math id="jats-math-93" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>V</mml:mi><mml:msub><mml:mtext>bile</mml:mtext><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>), clearance for bile excretion of unbound M1 (<mml:math id="jats-math-94" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi><mml:msub><mml:mtext>bile</mml:mtext><mml:mi>u</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>), and the release rate constant from gall bladder (<mml:math id="jats-math-95" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>k</mml:mi><mml:mi>rel</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math>)]. Unbound concentrations of M2 were described using a one&#8208;compartment model (volume <mml:math id="jats-math-96" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>), and linear elimination (<mml:math id="jats-math-97" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CL</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>). M2 formation from the parent compound central compartment was modeled using Michaelis&#8211;Menten kinetics (rate constant <mml:math id="jats-math-98" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">Km</mml:mi></mml:mrow></mml:mrow></mml:math> and maximum velocity <mml:math id="jats-math-99" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>V</mml:mi><mml:mi>max</mml:mi></mml:mrow></mml:mrow></mml:math>). Pain score data was best described using inhibitory Emax model (<mml:math id="jats-math-100" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>max</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi mathvariant="italic">IC</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-101" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>) with effect compartment to capture the delay (<mml:math id="jats-math-102" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">ke</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math>). Individual predicted unbound concentration of (<italic toggle="yes">1R,2R</italic>)&#8208;M1 was linked to effect compartment.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PSP4-14-781-g003.jpg"/></fig><fig position="float" fig-type="FIGURE" id="psp413315-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Predicted correction Visual Predictive Check (PcVPC) plots for the final model for unbound (<italic toggle="yes">1R,2R</italic>)&#8208;tramadol (a), total (<italic toggle="yes">1R,2R</italic>)&#8208;tramadol (b), unbound (<italic toggle="yes">1R,2R</italic>)&#8208;M1 (c), total (<italic toggle="yes">1R,2R</italic>)&#8208;M1 (d), and unbound (<italic toggle="yes">1R,2R</italic>)&#8208;M2 (e) models after a single oral administration of 100&#8201;mg rac&#8208;tramadol in non&#8208;diabetic patients with neuropathic pain (<italic toggle="yes">n</italic>&#8201;=&#8201;12), and in patients with diabetic neuropathic pain with T1DM (<italic toggle="yes">n</italic>&#8201;=&#8201;9) and T2DM (<italic toggle="yes">n</italic>&#8201;=&#8201;9). Visual Predictive Check plot for pain score PD model (f). Open circles represent prediction&#8208;corrected observed concentrations. Blue bins represent a simulation&#8208;based 95% CI for 5th and 95th prediction percentiles of prediction&#8208;corrected concentrations, whereas red bin represents a simulation&#8208;based 95% CI for 50th prediction percentiles of prediction&#8208;corrected concentrations. Black dashed lines represent the observed 5th and 95th percentiles of prediction&#8208;corrected concentrations of 500 simulated data, whereas the black line represents the observed 50th percentile of prediction&#8208;corrected concentrations of 500 simulated data. T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PSP4-14-781-g002.jpg"/></fig><p>The estimated apparent central and peripheral volume of distributions of (<italic toggle="yes">1R,2R</italic>)&#8208;tramadol and (<italic toggle="yes">1S,2S</italic>)&#8208;tramadol, 439 [L] and 465 [L], respectively, were similar, indicating that enantioselectivity does not affect the distribution phase. The apparent central volume of distribution of unbound tramadol was affected by BMI for both enantiomers. This finding can be attributed to the high lipophilicity of tramadol, with a logP of 2.7 [<xref rid="psp413315-bib-0034" ref-type="bibr">34</xref>]. Tramadol is primarily metabolized to M1 by CYP2D6 [<xref rid="psp413315-bib-0012" ref-type="bibr">12</xref>, <xref rid="psp413315-bib-0035" ref-type="bibr">35</xref>]. The clearance for the formation of M1 was approximately two&#8208;fold higher for (<italic toggle="yes">1S,2S</italic>)&#8208;tramadol compared to (<italic toggle="yes">1R,2R</italic>)&#8208;tramadol, suggesting that CYP2D6&#8208;mediated metabolism favors the formation of (<italic toggle="yes">1S,2S</italic>)&#8208;M1, confirming previous observations in healthy volunteers [<xref rid="psp413315-bib-0036" ref-type="bibr">36</xref>]. Covariate analysis identified CYP2D6 in&#160;vivo activity as a significant factor influencing the apparent clearance for the formation of unbound M1, showing a positive relationship.</p><p>Though it is not pharmacologically active, the M2 metabolite contributes to the excretion of around 10% of tramadol dose in human urine [<xref rid="psp413315-bib-0037" ref-type="bibr">37</xref>]. Our analysis estimated the fraction of tramadol converted to (<italic toggle="yes">1R,2R</italic>)&#8208;M2 to be 10% for and (<italic toggle="yes">1S,2S</italic>)&#8208;M2 to be 22.5% (Table&#160;<xref rid="psp413315-tbl-0001" ref-type="table">1</xref>; Figure&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S17</xref>). The unbound concentrations of <italic toggle="yes">(1R,2R)&#8208;</italic> and <italic toggle="yes">(1S,2S)&#8208;</italic>M2 were best described by a one&#8208;compartment model with non&#8208;linear formation and linear elimination, using individual post hoc parameter estimates from Steps 1 and 2 (Step 3, Table&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S5</xref>). As M2 is further metabolized to N,O&#8208;desmethyltramadol (M5) via CYP2D6 [<xref rid="psp413315-bib-0035" ref-type="bibr">35</xref>], CYP2D6 activity was tested as a covariate for the apparent clearance of unbound M2. The inclusion of CYP2D6 successfully captured the large interindividual variability in M2 exposure, confirming the relevance of CYP2D6 activity not only for M1 but also for M2.</p><table-wrap position="float" id="psp413315-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Parameter estimates for final population PK/PD model of tramadol, O&#8208;desmethyl tramadol (M1), N&#8208;desmethyl tramadol (M2), and pain score.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Parameter</th><th align="center" rowspan="2" valign="bottom" colspan="1">Description</th><th align="center" colspan="2" valign="bottom" rowspan="1">
<italic toggle="yes">1R,2R</italic> &#8208; Tramadol</th><th align="center" colspan="2" valign="bottom" rowspan="1">
<italic toggle="yes">1S,2S</italic> &#8208; Tramadol</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Estimate (RSE%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Bootstrap median (95% CI)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Estimate (RSE%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Bootstrap median (95% CI)</th></tr></thead><tbody valign="top"><tr><td align="left" colspan="6" valign="top" rowspan="1">
<bold>PK</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-103" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#945;</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Shape parameter</td><td align="center" valign="top" rowspan="1" colspan="1">2.96 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">2.91 (2.02, 4.37)</td><td align="center" valign="top" rowspan="1" colspan="1">3.63 (14.5)</td><td align="center" valign="top" rowspan="1" colspan="1">3.50 (2.61, 4.60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-104" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#947;</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Scale parameter</td><td align="center" valign="top" rowspan="1" colspan="1">0.147 (4.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.143 (0.023, 0.204)</td><td align="center" valign="top" rowspan="1" colspan="1">0.087 (4.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.100 (0.011, 0.184)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-105" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#946;</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Location parameter</td><td align="center" valign="top" rowspan="1" colspan="1">0.762 (4.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.753 (0.56, 1.088)</td><td align="center" valign="top" rowspan="1" colspan="1">0.779 (10.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.777 (0.623, 0.963)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-106" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vc</mml:mi><mml:mrow><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-107" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mi>L</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Apparent central volume of distribution of unbound tramadol</td><td align="center" valign="top" rowspan="1" colspan="1">63.4 (2.3)</td><td align="center" valign="top" rowspan="1" colspan="1">75.8 (35.07, 159.5)</td><td align="center" valign="top" rowspan="1" colspan="1">78.1 (9.6)</td><td align="center" valign="top" rowspan="1" colspan="1">72.6 (42.5, 123.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-108" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter of BMI on <mml:math id="jats-math-109" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vp</mml:mi><mml:mrow><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">3.87 (8.5)</td><td align="center" valign="top" rowspan="1" colspan="1">3.37 (1.21, 6.19)</td><td align="center" valign="top" rowspan="1" colspan="1">3.43 (30.6)</td><td align="center" valign="top" rowspan="1" colspan="1">3.54 (2.14, 5.16)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-110" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vp</mml:mi><mml:mrow><mml:mtext>peripheral</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-111" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mi>L</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Apparent peripheral volume of distribution of unbound tramadol</td><td align="center" valign="top" rowspan="1" colspan="1">439 (1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">435.0 (382.8, 494.7)</td><td align="center" valign="top" rowspan="1" colspan="1">465 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">473.8 (425.1, 516.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-112" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>Q</mml:mi><mml:mrow><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-113" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mrow><mml:mi>L</mml:mi><mml:mo>/</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Apparent intercompartmental clearance of unbound tramadol</td><td align="center" valign="top" rowspan="1" colspan="1">299 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">292.4(238.0, 360.2)</td><td align="center" valign="top" rowspan="1" colspan="1">337 (6.1)</td><td align="center" valign="top" rowspan="1" colspan="1">337.9 (279.1, 407.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-114" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Kb</mml:mi><mml:mtext>parent</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Binding proportionality constant of tramadol</td><td align="center" valign="top" rowspan="1" colspan="1">0.718 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.705 (0.387, 1.150)</td><td align="center" valign="top" rowspan="1" colspan="1">0.774 (9.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.53 (0.44, 0.64)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-115" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">fu</mml:mi><mml:mtext>parent</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fraction unbound of tramadol of non&#8208;diabetic group, <mml:math id="jats-math-116" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi mathvariant="italic">Kb</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.582</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.564</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-117" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter of type 1 diabetes on <mml:math id="jats-math-118" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Kb</mml:mi><mml:mtext>parent</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.311 (24.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.332 (0.129, 0.918)</td><td align="center" valign="top" rowspan="1" colspan="1">0.15 (30.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.640 (1.342, 2.011)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-119" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter of type 2 diabetes on <mml:math id="jats-math-120" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Kb</mml:mi><mml:mtext>parent</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.95 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.941 (0.448, 1.888)</td><td align="center" valign="top" rowspan="1" colspan="1">0.93 (56.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.06 (0.82, 1.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-121" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mi mathvariant="normal">&#945;</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability of <mml:math id="jats-math-122" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#945;</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.1 (29.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10 (0.030, 0.340)</td><td align="center" valign="top" rowspan="1" colspan="1">0.155 (44.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.145 (0.063, 0.260)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-123" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability of <mml:math id="jats-math-124" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">&#946;</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.441 (47.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.399 (0.221, 0.749)</td><td align="center" valign="top" rowspan="1" colspan="1">0.323 (65.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.324 (0.175, 0.531)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-125" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vp</mml:mi><mml:mrow><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability of <mml:math id="jats-math-126" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Vp</mml:mi><mml:mrow><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.29 (50.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.003 (0.220, 2.215)</td><td align="center" valign="top" rowspan="1" colspan="1">1.09 (58.8)</td><td align="center" valign="top" rowspan="1" colspan="1">1.014 (0.306, 1.957)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-127" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:msub><mml:mi mathvariant="italic">Kb</mml:mi><mml:mtext>parent</mml:mtext></mml:msub><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability of <mml:math id="jats-math-128" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Kb</mml:mi><mml:mtext>parent</mml:mtext></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.693 (46.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.546 (0.314, 1.017)</td><td align="center" valign="top" rowspan="1" colspan="1">0.637 (56.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.058 (0.029, 0.093)</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">
<bold>Metabolite</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-129" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CLF</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>L</mml:mi><mml:mo>/</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Clearance formation of unbound M1</td><td align="center" valign="top" rowspan="1" colspan="1">58.8 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">67.9 (48.94, 171.11)</td><td align="center" valign="top" rowspan="1" colspan="1">159 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">175.9 (132.7, 277.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-130" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>4</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter of CYP2D6 activity on <mml:math id="jats-math-131" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CLF</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.523 (25.2)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.18 (&#8722;0.680, &#8722;0.611)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.161 (61.4)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.178 (&#8722;0.423, 0.241)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-132" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>met</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:msup><mml:mi>h</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Absorption rate of first&#8208;pass metabolism</td><td align="center" valign="top" rowspan="1" colspan="1">0.796 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.76 (0.449, 1.774)</td><td align="center" valign="top" rowspan="1" colspan="1">1.51 (1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.64 (1.31, 3.26)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-133" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Kb</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Binding proportionality constant of M1 of the non&#8208;diabetic group</td><td align="center" valign="top" rowspan="1" colspan="1">3.07 (17.2)</td><td align="center" valign="top" rowspan="1" colspan="1">3.119 (2.404, 6.403)</td><td align="center" valign="top" rowspan="1" colspan="1">3.65 (2.2)</td><td align="center" valign="top" rowspan="1" colspan="1">3.497 (2.624, 4.888)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-134" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">fu</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fraction unbound of M1 of the non&#8208;diabetic group, <mml:math id="jats-math-135" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi mathvariant="italic">Kb</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.246</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.215</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-136" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>5</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter of type 1 diabetes on <mml:math id="jats-math-137" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Kb</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.105 (6.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.111 (0.081, 0.247)</td><td align="center" valign="top" rowspan="1" colspan="1">0.414 (1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.388 (0.193, 0.536)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-138" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>6</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter of type 2 diabetes on <mml:math id="jats-math-139" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">Kb</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.821 (7.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.808 (0.416, 1.290)</td><td align="center" valign="top" rowspan="1" colspan="1">0.467 (1.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.461 (0.321, 0.673)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">FRAC</italic>
</td><td align="center" valign="top" rowspan="1" colspan="1">Partition parameter to estimate fraction of first&#8208;pass metabolism</td><td align="center" valign="top" rowspan="1" colspan="1">0.0661 (2.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.053 (0.026, 0.074)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0639 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0596 (0.029, 0.079)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-140" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fp</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fraction of first&#8208;pass metabolism (<mml:math id="jats-math-141" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fp</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mfenced close=")" open="("><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mtext mathvariant="italic">FRAC</mml:mtext></mml:mrow></mml:mfrac></mml:mfenced></mml:mrow></mml:mrow></mml:math>) [%]</td><td align="center" valign="top" rowspan="1" colspan="1">6.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">6.0</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-142" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi><mml:msub><mml:mtext>bile</mml:mtext><mml:mi>u</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mi>L</mml:mi><mml:mo>/</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Clearance for bile excretion of unbound M1</td><td align="center" valign="top" rowspan="1" colspan="1">382 (2.9)</td><td align="center" valign="top" rowspan="1" colspan="1">382.1 (250, 746)</td><td align="center" valign="top" rowspan="1" colspan="1">406 (4.6)</td><td align="center" valign="top" rowspan="1" colspan="1">411.0 (324.6, 733.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-143" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>K</mml:mi><mml:mi>rel</mml:mi></mml:mrow><mml:mi>u</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:msup><mml:mi>h</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Release rate constant from gall bladder</td><td align="center" valign="top" rowspan="1" colspan="1">0.0019 (4.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0018 (0.0010, 0.0027)</td><td align="center" valign="top" rowspan="1" colspan="1">0.039 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.031 (0.012, 0.038)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-144" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext mathvariant="italic">STARTTIME</mml:mtext></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-145" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mi>h</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Bile release starting time</td><td align="center" valign="top" rowspan="1" colspan="1">2.85 (1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">2.670 (1.305, 6.678)</td><td align="center" valign="top" rowspan="1" colspan="1">2.53 (1.0)</td><td align="center" valign="top" rowspan="1" colspan="1">2.35 (1.10, 3.73)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-146" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext mathvariant="italic">DURATION</mml:mtext></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-147" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mi>h</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Bile release duration</td><td align="center" valign="top" rowspan="1" colspan="1">6.15 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">5.532 (2.28, 11.51)</td><td align="center" valign="top" rowspan="1" colspan="1">7.99 (0.9)</td><td align="center" valign="top" rowspan="1" colspan="1">7.70 (4.01, 9.70)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-148" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CL</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-149" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mrow><mml:mi>L</mml:mi><mml:mo>/</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Apparent clearance for unbound M1</td><td align="center" valign="top" rowspan="1" colspan="1">42 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">37.26 (19.32, 87.40)</td><td align="center" valign="top" rowspan="1" colspan="1">120 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">113.676 (70.769, 236.966)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-150" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-151" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mi>L</mml:mi></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Apparent volume of distribution of unbound M2</td><td align="center" valign="top" rowspan="1" colspan="1">3.13 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">3.117 (2.248, 3.758)</td><td align="center" valign="top" rowspan="1" colspan="1">2.03 (6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.94 (1.29, 2.32)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-152" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CL</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-153" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mrow><mml:mi>L</mml:mi><mml:mo>/</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Apparent clearance for unbound M2</td><td align="center" valign="top" rowspan="1" colspan="1">7.75 (1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">7.703 (5.734, 9.513)</td><td align="center" valign="top" rowspan="1" colspan="1">13.4 (2.0)</td><td align="center" valign="top" rowspan="1" colspan="1">13.2 (10.6, 16.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-154" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>7</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter of CYP2D6 activity on <mml:math id="jats-math-155" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CL</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.477 (10.1)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.416 (&#8722;0.714, &#8722;0.083)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.401 (10.1)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8722;0.553 (&#8722;0.880, &#8722;0.244)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-156" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mtext mathvariant="italic">CLother</mml:mtext><mml:mrow><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-157" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mrow><mml:mi>L</mml:mi><mml:mo>/</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Unbound drug clearance from central compartment</td><td align="center" valign="top" rowspan="1" colspan="1">36.4 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">36.7 (32.1, 48.9)</td><td align="center" valign="top" rowspan="1" colspan="1">38.6 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">40.93 (35.81, 55.56)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-158" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fraction of tramadol converted to M1</td><td align="center" valign="top" rowspan="1" colspan="1">0.538 (0.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.533 (0.508, 0.545)</td><td align="center" valign="top" rowspan="1" colspan="1">0.415 (1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.411 (0.390, 0.422)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-159" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fraction of tramadol converted to M2 (<mml:math id="jats-math-160" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:mrow></mml:math> 1&#8201;&#8211;&#8201;<mml:math id="jats-math-161" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>&#8201;&#8211;&#8201;<mml:math id="jats-math-162" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fp</mml:mi></mml:mrow></mml:mrow></mml:math>&#8201;&#8211;&#8201;0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">0.225</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-163" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mfenced close="]" open="["><mml:mrow><mml:mtext>nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Maximum reaction velocity</td><td align="center" valign="top" rowspan="1" colspan="1">98.6 (0.3)</td><td align="center" valign="top" rowspan="1" colspan="1">99.3 (84.3, 145.49)</td><td align="center" valign="top" rowspan="1" colspan="1">139 (1.6)</td><td align="center" valign="top" rowspan="1" colspan="1">138.7 (115.3, 244.6)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-164" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">Km</mml:mi></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-165" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:mrow><mml:mtext>nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Michaelis&#8211;Menten constant of formation of unbound M2</td><td align="center" valign="top" rowspan="1" colspan="1">16,300 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">16,066 (12,357, 20,989)</td><td align="center" valign="top" rowspan="1" colspan="1">21,500 (1.8)</td><td align="center" valign="top" rowspan="1" colspan="1">21,383 (17,928, 43,309)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-166" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:msub><mml:mi mathvariant="italic">CLF</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability for <mml:math id="jats-math-167" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CLF</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.726 (73.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.659 (0.060, 1.322)</td><td align="center" valign="top" rowspan="1" colspan="1">0.304 (69.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.266 (0.075, 0.357)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-168" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:mi mathvariant="italic">Kb</mml:mi><mml:mn>2</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability for <mml:math id="jats-math-169" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">Kb</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.43 (86)</td><td align="center" valign="top" rowspan="1" colspan="1">0.431 (0.081, 0.931)</td><td align="center" valign="top" rowspan="1" colspan="1">0.119 (54.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.144 (0.075, 0.655)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-170" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:msub><mml:mtext mathvariant="italic">CLbile</mml:mtext><mml:mi>u</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability for <mml:math id="jats-math-171" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">CL</mml:mi><mml:msub><mml:mtext>bile</mml:mtext><mml:mi>u</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.487 (83)</td><td align="center" valign="top" rowspan="1" colspan="1">0.478 (0.185, 0.916)</td><td align="center" valign="top" rowspan="1" colspan="1">0.276 (55.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.347 (0.253, 0.637)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-172" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mrow><mml:msub><mml:mi mathvariant="italic">CL</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability for <mml:math id="jats-math-173" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">CL</mml:mi><mml:mrow><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>F</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.443 (60)</td><td align="center" valign="top" rowspan="1" colspan="1">0.442 (0.162, 0.819)</td><td align="center" valign="top" rowspan="1" colspan="1">0.332 (47.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.332 (0.114, 0.661)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-174" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">V</mml:mi><mml:mi mathvariant="bold">max</mml:mi></mml:msub><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability for <mml:math id="jats-math-175" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>V</mml:mi><mml:mi>max</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.415 (56.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.414 (0.145, 0.699)</td><td align="center" valign="top" rowspan="1" colspan="1">0.574 (98.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.572 (0.061, 1.513)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-176" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:mi mathvariant="bold-italic">Km</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variability for Km</td><td align="center" valign="top" rowspan="1" colspan="1">1.99 (44.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1.99 (1.13, 3.40)</td><td align="center" valign="top" rowspan="1" colspan="1">2.51 (61.4)</td><td align="center" valign="top" rowspan="1" colspan="1">2.50 (1.38, 4.02)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-177" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mtext>prop</mml:mtext><mml:mo>,</mml:mo><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Proportional residual error variability of unbound tramadol</td><td align="center" valign="top" rowspan="1" colspan="1">0.044 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.044 (0.035, 0.058)</td><td align="center" valign="top" rowspan="1" colspan="1">0.043 (4.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.043 (0.032, 0.053)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-178" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mtext>prop</mml:mtext><mml:mo>,</mml:mo><mml:mtext>parent</mml:mtext><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Proportional residual error variability of total tramadol</td><td align="center" valign="top" rowspan="1" colspan="1">0.041 (4.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.041 (0.033, 0.051)</td><td align="center" valign="top" rowspan="1" colspan="1">0.039 (3.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.039 (0.030, 0.047)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-179" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mtext>prop</mml:mtext><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Proportional residual error variability of unbound M1</td><td align="center" valign="top" rowspan="1" colspan="1">0.181 (3.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.182 (0.151, 0.222)</td><td align="center" valign="top" rowspan="1" colspan="1">0.161 (4.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.162 (0.132, 0.203)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-180" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mtext>prop</mml:mtext><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Proportional residual error variability of total tramadol</td><td align="center" valign="top" rowspan="1" colspan="1">0.217 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.217 (0.174, 0.279)</td><td align="center" valign="top" rowspan="1" colspan="1">0.234 (4.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.236 (0.161, 0.344)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-181" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mrow><mml:mtext>prop</mml:mtext><mml:mo>,</mml:mo><mml:mi>M</mml:mi><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>u</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Proportional residual error variability of unbound M2</td><td align="center" valign="top" rowspan="1" colspan="1">0.083 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.083 (0.067, 0.101)</td><td align="center" valign="top" rowspan="1" colspan="1">0.096 (2.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.095 (0.071, 0.118)</td></tr><tr><td align="left" colspan="6" valign="top" rowspan="1">
<bold>Effect</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-182" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">ke</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
<mml:math id="jats-math-183" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfenced close="]" open="["><mml:msup><mml:mi>h</mml:mi><mml:mrow><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mfenced></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Delayed relative to the plasma concentration by a first order rate constant</td><td align="center" valign="top" rowspan="1" colspan="1">0.0398 (20.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.0513 (0.0004, 0.2330)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-184" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>max</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Maximum fraction of treatment effect of tramadol</td><td align="center" valign="top" rowspan="1" colspan="1">0.908 (5.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.952 (0.767, 0.999)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-185" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Baseline score when no drug is present at time t&#8201;=&#8201;0</td><td align="center" valign="top" rowspan="1" colspan="1">0.464 (3.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.452 (0.282, 0.624)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">IC</italic>
<sub>
<italic toggle="yes">50</italic>
</sub> [<mml:math id="jats-math-186" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>nmol</mml:mtext><mml:mo>/</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:mrow></mml:math>]</td><td align="center" valign="top" rowspan="1" colspan="1">Non&#8208;diabetic group</td><td align="center" valign="top" rowspan="1" colspan="1">2.36 (9.3)</td><td align="center" valign="top" rowspan="1" colspan="1">2.79 (0.03, 22.07)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-187" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>8</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter T1DM on <italic toggle="yes">IC</italic>
<sub>
<italic toggle="yes">50</italic>
</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.229 (12.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.224 (0.025, 0.997)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-188" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="normal">&#946;</mml:mi><mml:mn>9</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Fixed effect parameter T2DM on <italic toggle="yes">IC</italic>
<sub>
<italic toggle="yes">50</italic>
</sub>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.431 (10.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.422 (0.056, 2.108)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-189" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mi mathvariant="bold">max</mml:mi></mml:msub><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variance for<mml:math id="jats-math-190" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mspace width="0.25em"/><mml:mi>I</mml:mi><mml:mi>max</mml:mi></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">8.97 (63.3)</td><td align="center" valign="top" rowspan="1" colspan="1">13.64 (1.83, 54.28)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-191" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#969;</mml:mi><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Interindividual variance for <mml:math id="jats-math-192" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">PD</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">2.47 (56.7)</td><td align="center" valign="top" rowspan="1" colspan="1">2.076 (0.909, 3.235)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<mml:math id="jats-math-193" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mi>&#963;</mml:mi><mml:mi>add</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:math>
</td><td align="center" valign="top" rowspan="1" colspan="1">Additive residual error variability of pain score</td><td align="center" valign="top" rowspan="1" colspan="1">0.713 (8.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.701 (0.572, 0.891)</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td><td align="center" valign="top" rowspan="1" colspan="1">&#8212;</td></tr></tbody></table><table-wrap-foot id="psp413315-ntgp-0002"><fn id="psp413315-note-0002"><p>Abbreviations: <mml:math id="jats-math-194" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>&#969;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math>, Interindividual variability; <mml:math id="jats-math-195" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mi>&#963;</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math>, Residual error variability.</p></fn></table-wrap-foot></table-wrap><p>Diabetes was identified as a significant categorical covariate affecting the <mml:math id="jats-math-196" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi></mml:mrow></mml:mrow></mml:math> of tramadol and M1 (Table&#160;<xref rid="psp413315-tbl-0001" ref-type="table">1</xref>, Figure&#160;<xref rid="psp413315-fig-0001" ref-type="fig">1</xref>). Patients with T1DM and T2DM exhibited a higher <mml:math id="jats-math-197" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi></mml:mrow></mml:mrow></mml:math> of M1 compared to non&#8208;diabetic and T2DM patients. Since the investigated subjects with diabetes had poor glycemic control with median (min&#8208;max) HbA1C levels of 10.7 (8%&#8211;15.7%), the increased <mml:math id="jats-math-198" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi></mml:mrow></mml:mrow></mml:math> can be attributed to the high glucose levels, which may displace drugs from plasma protein binding sites [<xref rid="psp413315-bib-0033" ref-type="bibr">33</xref>]. Furthermore, simulations following 100&#8201;mg single dose administration of 500 subjects across diabetes groups were conducted. The AUC of total <italic toggle="yes">(1R,2R)&#8208;</italic>tramadol and total <italic toggle="yes">(1R,2R)&#8208;</italic>M1 were 67% and 14% reduced for T1DM and T2DM patients respectively compared to non&#8208;diabetic patients (Figure&#160;<xref rid="psp413315-fig-0003" ref-type="fig">3</xref>). Also, simulation analysis demonstrated that the unbound fractions of tramadol and M1 in both enantiomers were higher in participants with both type 1 and type 2 diabetes (Figure&#160;<xref rid="psp413315-fig-0004" ref-type="fig">4</xref>). Despite the discrepancies in <mml:math id="jats-math-199" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi></mml:mrow></mml:mrow></mml:math> of tramadol and M1 in both enantiomers, exposure to the unbound &#956;&#8208;opioid agonist <italic toggle="yes">(1R,2R)</italic>&#8208;M1 remained unchanged in subjects with T1DM nor T2DM (Figure&#160;<xref rid="psp413315-fig-0003" ref-type="fig">3</xref>).</p><fig position="float" fig-type="FIGURE" id="psp413315-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Effect of diabetes on exposure (AUC<sub>0&#8208;24</sub> and <italic toggle="yes">C</italic>
<sub>max</sub>) of unbound and total (<italic toggle="yes">1R,2R</italic>)&#8208; tramadol and the active <italic toggle="yes">(1R,2R)&#8208;</italic>M1 following the administration of 100&#8201;mg tramadol single dose. Simulations were carried out in 500 subjects for each group, which were defined as subjects with T1DM and T2DM and subjects without diabetes. Results are presented as ratios of median (blue circle) along with 95% CI (horizontal lines) assuming subjects without diabetes as reference. The shadowed area represents 20% difference from the reference. For this simulation, other significant covariates, including BMI and CYP2D6 in&#160;vivo activity and in the model were set to median values. 95% CI for median were calculated using the following equation, <mml:math id="jats-math-200" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">nq</mml:mi><mml:mo>&#177;</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mn>0.975</mml:mn></mml:msub><mml:msqrt><mml:mrow><mml:mi mathvariant="italic">nq</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:mi>q</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt><mml:mo>,</mml:mo><mml:mi>q</mml:mi><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-201" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mn>0.975</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>1.96</mml:mn></mml:mrow></mml:mrow></mml:math>. T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PSP4-14-781-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="psp413315-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Simulated fraction unbound for (<italic toggle="yes">1R,2R</italic>)&#8208;tramadol and metabolite (<italic toggle="yes">1R,2R</italic>)&#8208;O&#8208;desmethyltramadol (M1) and (<italic toggle="yes">1S,2S</italic>)&#8208;tramadol and (<italic toggle="yes">1S,2S</italic>)&#8208;O&#8208;desmethyltramadol (M1) across different diabetes groups (<italic toggle="yes">n</italic>&#8201;=&#8201;500), following the administration of 100&#8201;mg tramadol single dose.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="PSP4-14-781-g004.jpg"/></fig><p>Our assessment identified 3 patients as non&#8208;responders to a single dose of tramadol regarding pain score reduction within this cohort (more details on data exclusion criteria are provided in the Supporting Information). Since a delay in the PD response was observed respective to the plasma concentrations of the active unbound <italic toggle="yes">(1R,2R)</italic>&#8208;M1 (Supp Material, Figure&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S2</xref>), an Imax model with an effect compartment was used to describe the PK/PD relationship (Figure&#160;<xref rid="psp413315-fig-0001" ref-type="fig">1</xref>, Table&#160;<xref rid="psp413315-tbl-0001" ref-type="table">1</xref>). Further details on parameter estimates, GOF plots, and VPCs are provided in the Supporting Information (Figures&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S5&#8211;S17</xref>; Tables&#160;<xref rid="psp413315-supitem-0001" ref-type="supplementary-material">S3&#8211;S5</xref>). The unbound concentration of <italic toggle="yes">(1R,2R)</italic>&#8208;M1 required to achieve 50% of the maximum pain reduction (IC<sub>50</sub>) was estimated at 2.91 [nmol/L] for patients without diabetes, which corresponds to 725.61&#8201;ng/L. Diabetes was identified as a significant categorical covariate on IC<sub>50</sub>, signifying that patients with both T1DM and T2DM showed increased sensitivity to the drug (Table&#160;<xref rid="psp413315-tbl-0001" ref-type="table">1</xref>). The IC<sub>50</sub> for T1DM was estimated at 0.156 [nmol/L] and for T2DM at 0.515 [nmol/L]. As a consequence, subjects with neuropathic pain due to nerve compression mechanisms experience lower response rates if treated with similar doses as patients with diabetic neuropathic pain (Figure&#160;<xref rid="psp413315-fig-0005" ref-type="fig">5</xref>).</p><fig position="float" fig-type="FIGURE" id="psp413315-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Median of pain reduction of simulated 500 subjects across different diabetes groups throughout 3&#8201;days following the administration of 50, 100, 200, and 400&#8201;mg tramadol at Q24h and Q12h dosing frequencies; (a) non&#8208;diabetic group (q.d.), (b) non&#8208;diabetic group (b.i.d.), (c) T1DM (q.d.), (d) T1DM (b.i.d.), (e) T2DM (q.d.), and (f) T2DM (b.i.d.). The pain scores of each individual were normalized by their baseline values. T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="PSP4-14-781-g005.jpg"/></fig></sec><sec id="psp413315-sec-0014"><label>3.3</label><title>Simulations</title><p>Recognizing the diabetes effect on tramadol PK and PD, the developed PK&#8208;PD link model was employed to simulate novel dosing strategies for tramadol. Dose escalation simulations revealed that at the lowest dose of 50&#8201;mg once daily, sustained pain relief was substantial only for 22.4% in patients with neuropathic pain secondary to nerve compression mechanisms. However, this percentage increased to 61% for patients with T1DM and 51% for patients with T2DM. This difference is attributed to diabetes affecting tramadol's IC<sub>50</sub> in neuropathic pain, with diabetic neuropathic pain being more responsive to tramadol than neuropathic pain secondary to radicular compression and median nerve compression. Our simulations suggest that a daily dose of 100&#8201;mg (q.d.) can alleviate neuropathic pain in over 80% of patients with T1DM or T2DM, considering both substantial and moderate responses. However, the same dosing regimen resulted in a lower response in patients with neuropathic pain secondary to nerve compression mechanisms. Specifically, our simulations showed that 43% of patients experienced substantial pain relief, while 23% responded with moderate pain relief. Interestingly, patients with neuropathic pain secondary to nerve compression mechanisms benefit more from a twice&#8208;daily dosing regimen. Simulations using 100&#8201;mg twice daily resulted in over 80% of responders in this subgroup.</p></sec></sec><sec sec-type="discussion" id="psp413315-sec-0015"><label>4</label><title>Discussion</title><p>A comprehensive population PK/PD link model was developed to account for tramadol enantiomers and their primary metabolites, M1 and M2, in patients with neuropathic pain from various causes. The model accounts for the complex PK of tramadol, including specific parameter estimates for each enantiomer resulting from the enantioselective pharmacokinetics [<xref rid="psp413315-bib-0006" ref-type="bibr">6</xref>, <xref rid="psp413315-bib-0007" ref-type="bibr">7</xref>], first&#8208;pass metabolism, plasma protein binding and unbound drug concentration, and enterohepatic circulation for M1 metabolite [<xref rid="psp413315-bib-0010" ref-type="bibr">10</xref>]. The pain attenuation response was linked to the unbound concentrations of the active (<italic toggle="yes">1R,2R</italic>)&#8208;M1 metabolite using an effect compartment to account for the delay between exposure and response. Our results demonstrated a superior analgesic effect of tramadol in diabetic neuropathic pain (T1DM and T2DM) compared to neuropathic pain secondary to radicular compression and median nerve compression. Our simulations indicated that over 80% of patients with neuropathic pain secondary to diabetes are likely to respond to a once&#8208;daily dose of 100&#8201;mg of tramadol, most of them with substantial pain attenuation at 72&#8208;h, defined as a 50% reduction in baseline pain score (Table&#160;<xref rid="psp413315-tbl-0002" ref-type="table">2</xref>). However, patients with neuropathic pain due to nerve compression mechanisms are more likely to respond to twice&#8208;daily administration of tramadol. For instance, 83% of responders are expected with 100&#8201;mg dose every 12&#8201;h, compared to 64% and 76.4% of responders following 100&#8201;mg and 200&#8201;mg once daily (Table&#160;<xref rid="psp413315-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="psp413315-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Percentage of subjects achieving substantial or moderate pain relief across groups without diabetes, T1DM and T2DM.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">Regimen</th><th align="center" rowspan="2" valign="bottom" colspan="1">Dose/day [mg]</th><th align="center" colspan="3" valign="bottom" rowspan="1">Maximum pain relief</th><th align="center" colspan="3" valign="bottom" rowspan="1">Sustained pain relief</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">Non&#8208;diabetic</th><th align="center" valign="bottom" rowspan="1" colspan="1">T1DM</th><th align="center" valign="bottom" rowspan="1" colspan="1">T2DM</th><th align="center" valign="bottom" rowspan="1" colspan="1">Non&#8208;diabetic</th><th align="center" valign="bottom" rowspan="1" colspan="1">T1DM</th><th align="center" valign="bottom" rowspan="1" colspan="1">T2DM</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">50&#8201;mg q.d.</td><td align="center" valign="top" rowspan="1" colspan="1">50</td><td align="center" valign="top" rowspan="1" colspan="1">72.0/12.6</td><td align="center" valign="top" rowspan="1" colspan="1">78.2/7.2</td><td align="center" valign="top" rowspan="1" colspan="1">81.8/6.2</td><td align="center" valign="top" rowspan="1" colspan="1">22.4/29.6</td><td align="center" valign="top" rowspan="1" colspan="1">61.0/17.0</td><td align="center" valign="top" rowspan="1" colspan="1">51.0/22.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">100&#8201;mg q.d.</td><td align="center" valign="top" rowspan="1" colspan="1">100</td><td align="center" valign="top" rowspan="1" colspan="1">74.6/10.4</td><td align="center" valign="top" rowspan="1" colspan="1">78.4/7.0</td><td align="center" valign="top" rowspan="1" colspan="1">82.6/5.4</td><td align="center" valign="top" rowspan="1" colspan="1">43.0/23.0</td><td align="center" valign="top" rowspan="1" colspan="1">70.4/11.6</td><td align="center" valign="top" rowspan="1" colspan="1">65.0/15.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">150&#8201;mg q.d.</td><td align="center" valign="top" rowspan="1" colspan="1">150</td><td align="center" valign="top" rowspan="1" colspan="1">74.8/10.2</td><td align="center" valign="top" rowspan="1" colspan="1">78.4/7.0</td><td align="center" valign="top" rowspan="1" colspan="1">82.8/5.2</td><td align="center" valign="top" rowspan="1" colspan="1">54.2/19.2</td><td align="center" valign="top" rowspan="1" colspan="1">73.4/9.2</td><td align="center" valign="top" rowspan="1" colspan="1">72.0/10.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">200&#8201;mg q.d.</td><td align="center" valign="top" rowspan="1" colspan="1">200</td><td align="center" valign="top" rowspan="1" colspan="1">75.0/10.4</td><td align="center" valign="top" rowspan="1" colspan="1">78.6/7.0</td><td align="center" valign="top" rowspan="1" colspan="1">82.8/5.2</td><td align="center" valign="top" rowspan="1" colspan="1">59.0/17.4</td><td align="center" valign="top" rowspan="1" colspan="1">75.4/8.4</td><td align="center" valign="top" rowspan="1" colspan="1">74.8/9.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">250&#8201;mg q.d.</td><td align="center" valign="top" rowspan="1" colspan="1">250</td><td align="center" valign="top" rowspan="1" colspan="1">75.2/10.2</td><td align="center" valign="top" rowspan="1" colspan="1">78.6/7.0</td><td align="center" valign="top" rowspan="1" colspan="1">82.8/5.2</td><td align="center" valign="top" rowspan="1" colspan="1">61.2/17.6</td><td align="center" valign="top" rowspan="1" colspan="1">75.4/8.4</td><td align="center" valign="top" rowspan="1" colspan="1">76.4/8.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">300&#8201;mg q.d.</td><td align="center" valign="top" rowspan="1" colspan="1">300</td><td align="center" valign="top" rowspan="1" colspan="1">75.2/10.2</td><td align="center" valign="top" rowspan="1" colspan="1">78.6/7.0</td><td align="center" valign="top" rowspan="1" colspan="1">82.8/5.2</td><td align="center" valign="top" rowspan="1" colspan="1">64.4/14.8</td><td align="center" valign="top" rowspan="1" colspan="1">76.0/8.0</td><td align="center" valign="top" rowspan="1" colspan="1">77.6/7.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">350&#8201;mg q.d.</td><td align="center" valign="top" rowspan="1" colspan="1">350</td><td align="center" valign="top" rowspan="1" colspan="1">75.6/9.8</td><td align="center" valign="top" rowspan="1" colspan="1">78.6/7.0</td><td align="center" valign="top" rowspan="1" colspan="1">83.0/5.0</td><td align="center" valign="top" rowspan="1" colspan="1">65.8/14.0</td><td align="center" valign="top" rowspan="1" colspan="1">76.0/8.2</td><td align="center" valign="top" rowspan="1" colspan="1">78.0/7.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">400&#8201;mg q.d.</td><td align="center" valign="top" rowspan="1" colspan="1">400</td><td align="center" valign="top" rowspan="1" colspan="1">75.6/9.8</td><td align="center" valign="top" rowspan="1" colspan="1">78.6/7.0</td><td align="center" valign="top" rowspan="1" colspan="1">83.0/5.0</td><td align="center" valign="top" rowspan="1" colspan="1">67.2/13.6</td><td align="center" valign="top" rowspan="1" colspan="1">76.4/7.8</td><td align="center" valign="top" rowspan="1" colspan="1">78.4/7.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">50&#8201;mg b.i.d</td><td align="center" valign="top" rowspan="1" colspan="1">100</td><td align="center" valign="top" rowspan="1" colspan="1">72.2/12.2</td><td align="center" valign="top" rowspan="1" colspan="1">78.0/7.4</td><td align="center" valign="top" rowspan="1" colspan="1">81.8/6.2</td><td align="center" valign="top" rowspan="1" colspan="1">61.2/17.4</td><td align="center" valign="top" rowspan="1" colspan="1">76.0/8.6</td><td align="center" valign="top" rowspan="1" colspan="1">77.4/9.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">100&#8201;mg b.i.d</td><td align="center" valign="top" rowspan="1" colspan="1">200</td><td align="center" valign="top" rowspan="1" colspan="1">74.8/10.2</td><td align="center" valign="top" rowspan="1" colspan="1">78.4/7.0</td><td align="center" valign="top" rowspan="1" colspan="1">82.6/5.4</td><td align="center" valign="top" rowspan="1" colspan="1">70.8/12.2</td><td align="center" valign="top" rowspan="1" colspan="1">77.2/7.6</td><td align="center" valign="top" rowspan="1" colspan="1">81.2/6.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">200&#8201;mg b.i.d</td><td align="center" valign="top" rowspan="1" colspan="1">400</td><td align="center" valign="top" rowspan="1" colspan="1">75.0/10.4</td><td align="center" valign="top" rowspan="1" colspan="1">78.4/7.2</td><td align="center" valign="top" rowspan="1" colspan="1">82.8/5.2</td><td align="center" valign="top" rowspan="1" colspan="1">73.4/11.0</td><td align="center" valign="top" rowspan="1" colspan="1">77.6/7.8</td><td align="center" valign="top" rowspan="1" colspan="1">81.8/6.2</td></tr></tbody></table><table-wrap-foot id="psp413315-ntgp-0003"><fn id="psp413315-note-0003"><p>
<italic toggle="yes">Note:</italic> Substantial pain relief is defined as &gt;&#8201;50% reduction from baseline score, while moderate pain relief is defined as a 30%&#8211;50% reduction from baseline score. Pain scores were assessed at the point of maximum pain relief and immediately before the next dose in a steady state condition (sustained pain relief evaluation).</p></fn><fn id="psp413315-note-0004"><p>Abbreviations: T1DM, type 1 diabetes; T2DM, type 2 diabetes.</p></fn></table-wrap-foot></table-wrap><p>The PK/PD model developed in this study provides valuable insights into tramadol PK and PD in treating chronic neuropathic pain. Diabetes can affect drug absorption, distribution, metabolism, and elimination in many ways [<xref rid="psp413315-bib-0038" ref-type="bibr">38</xref>]. Regarding protein binding, in&#160;vivo albumin glycation can displace the drug from its binding sites, increasing the fraction of the drug accessible for crossing membranes, reaching the target tissue or the eliminating organs, or being filtered in the glomerulus [<xref rid="psp413315-bib-0033" ref-type="bibr">33</xref>]. This is particularly important in patients with diabetes with poor glycemic control, such as in this particular cohort. Our findings indicate that despite the increased <mml:math id="jats-math-202" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="italic">fu</mml:mi></mml:mrow></mml:mrow></mml:math> of <italic toggle="yes">(1R,2R)&#8208;</italic>M1 in patients with T1DM, no differences were observed in the AUC of unbound active <italic toggle="yes">(1R,2R)&#8208;</italic>M1 comparing patients with or without diabetes. This observation can be attributed to tramadol's low&#8208;hepatic extraction status [<xref rid="psp413315-bib-0032" ref-type="bibr">32</xref>], suggesting that clinically relevant effects due to alterations in plasma protein binding are unlikely [<xref rid="psp413315-bib-0039" ref-type="bibr">39</xref>].</p><p>Tramadol is commonly administered to treat neuropathic pain [<xref rid="psp413315-bib-0040" ref-type="bibr">40</xref>], including diabetic neuropathic pain [<xref rid="psp413315-bib-0013" ref-type="bibr">13</xref>], which occurs in approximately 16% of patients diagnosed with diabetes [<xref rid="psp413315-bib-0036" ref-type="bibr">36</xref>]. Interestingly, tramadol exhibits a hypoglycemic effect in patients with T2DM [<xref rid="psp413315-bib-0041" ref-type="bibr">41</xref>]. The mechanism involves the activation of a neuronal insulin signaling cascade, specifically by increasing the expression of insulin receptor substrate&#8208;2. This activation was suppressed by the opioid antagonist naloxone and dexamethasone [<xref rid="psp413315-bib-0041" ref-type="bibr">41</xref>]. Also, tramadol's impact on glucose metabolism extends beyond the central nervous system. In diabetic rats lacking insulin, activating mu&#8208;opioid receptors by tramadol enhances glucose utilization and reduces hepatic gluconeogenesis, ultimately lowering plasma glucose levels [<xref rid="psp413315-bib-0042" ref-type="bibr">42</xref>]. Consequently, tramadol ameliorates peripheral glucose metabolism by activating mu&#8208;opioid receptors, highlighting the interconnectedness of central and peripheral glucose regulation [<xref rid="psp413315-bib-0041" ref-type="bibr">41</xref>].</p><p>Our data indicate that individuals with diabetes&#8208;induced neuropathic pain exhibit higher sensitivity to tramadol, as evidenced by the reduced IC<sub>50</sub>. The study shows that similar sustained pain reduction is achieved when patients with nerve compression&#8208;related neuropathic pain receive 200&#8201;mg q.d., while those with diabetes&#8208;induced neuropathic pain receive 50&#8201;mg q.d. Additionally, patients with diabetes may benefit from once&#8208;daily dosing of tramadol. In contrast, patients without diabetes may require a twice&#8208;daily dosing to achieve sufficient sustained pain reduction. A similar behavior was previously described for pregabalin, since patients with diabetic neuropathy showed higher response rates than patients with central pain and fibromyalgia, indicating that different neuropathic pain conditions should be treated separately [<xref rid="psp413315-bib-0043" ref-type="bibr">43</xref>].</p><p>High blood sugar levels can damage blood vessels and nerves over time [<xref rid="psp413315-bib-0044" ref-type="bibr">44</xref>, <xref rid="psp413315-bib-0045" ref-type="bibr">45</xref>]. In diabetic neuropathy, hyperglycemia initiates pathogenic changes, including post&#8208;translational protein modifications by glucose, increased glucose metabolism via aldose reductase and glycolysis, and other catabolic pathways. Interestingly, peripheral nerves contain insulin receptors that mediate the neurotrophic and neuro&#8208;supportive effects of insulin, independent of systemic glucose regulation [<xref rid="psp413315-bib-0046" ref-type="bibr">46</xref>, <xref rid="psp413315-bib-0047" ref-type="bibr">47</xref>]. The enhanced analgesic action following tramadol dosing likely results from its hypoglycemic effect and modulation of peripheral insulin receptors, ultimately ameliorating nociceptive fiber damage in diabetic neuropathy. In contrast, neuropathy due to compression (e.g., carpal tunnel syndrome and disc herniation) involves marked changes in intraneural microcirculation, nerve fiber structure, impaired axonal transport, and alterations in vascular permeability, leading to edema formation and nerve function deterioration [<xref rid="psp413315-bib-0048" ref-type="bibr">48</xref>].</p><p>Our findings indicate that increasing tramadol doses or frequency in T1DM and T2DM does not result in additional pain relief once the maximum effect is reached in diabetic patients. Numerous reports have highlighted significant adverse events associated with tramadol, particularly at higher doses. These adverse effects include dizziness, constipation, nausea, headache, and somnolence [<xref rid="psp413315-bib-0001" ref-type="bibr">1</xref>]. Additionally, high doses of tramadol induced fluctuations in blood glucose levels representing a potential side effect that has not received adequate attention. Such alterations in glucose levels could contribute to the likelihood of seizures in patients receiving high doses of tramadol [<xref rid="psp413315-bib-0049" ref-type="bibr">49</xref>].</p><p>In summary, our model&#8208;based PK/PD link approach offers valuable guidance for prescribers managing neuropathic chronic pain. For patients with diabetic neuropathic pain, a low IC<sub>50</sub> value supports the efficacy of once&#8208;daily dosing treatments. Conversely, patients with neuropathic pain secondary to nerve compression mechanisms, such as cervical or lumbar disc herniation and carpal tunnel syndrome, may require more frequent dosing, such as twice&#8208;daily dosing, to counteract lower sensitivity to tramadol. In both scenarios, dose titration is essential to prevent unnecessary high doses typically associated with adverse events. Despite the useful insights for clinical practice, our study has some limitations. Firstly, patients presenting vomiting following tramadol dosing (<italic toggle="yes">n</italic>&#8201;=&#8201;8 in a total of 38 patients, or 21% of all investigated patients) were excluded from the PK and PD analysis due to the drug loss, impairing both PK and PD assessments. This exclusion may have introduced bias in the response rates for this cohort. Additionally, three patients were identified as non&#8208;responders based on PD data and excluded from the PD assessment. Secondly, the use of allometric scaling may introduce some bias in parameter estimation. Furthermore, the clinical data used to build the model does not include information on long&#8208;term tramadol use, preventing an assessment of its prolonged effects. Tolerance to tramadol with extended use could result in a diminished response or necessitate higher doses for similar efficacy [<xref rid="psp413315-bib-0015" ref-type="bibr">15</xref>]. Our current model does not account for tolerance mechanisms. Additionally, although pain was assessed using the VAS pain score, it was evaluated over 24&#8201;h, which may have introduced variability in pain score records due to changes in patient alertness and mindset throughout the day. Despite these limitations, our study provides a detailed time course of pain scores, allowing for a comprehensive assessment of pain changes over time.</p></sec><sec id="psp413315-sec-0016"><title>Author Contributions</title><p>D.C., P.M., S.G., B.C., G.R.L, V.L.L., V.V., and N.M. wrote the manuscript. D.C., P.M., S.G., G.R.L, V.L.L., V.V., and N.M. designed the research. D.C., P.M., S.G., B.C., G.R.L, V.L.L., V.V., and N.M. performed the research. D.C., P.M., S.G., V.V., and N.M. analyzed the data.</p></sec><sec sec-type="COI-statement" id="psp413315-sec-0017"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="psp413315-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Data S1:</bold> Supporting Information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="PSP4-14-781-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="psp413315-bibl-0001"><title>References</title><ref id="psp413315-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="psp413315-cit-0001"><string-name name-style="western"><given-names>E.</given-names><surname>Cavalli</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mammana</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Nicoletti</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Bramanti</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Mazzon</surname></string-name>, &#8220;<article-title>The Neuropathic Pain: An Overview of the Current Treatment and Future Therapeutic Approaches</article-title>,&#8221; <source>International Journal of Immunopathology and Pharmacology</source><volume>33</volume> (<year>2019</year>): <elocation-id>2058738419838383</elocation-id>.<pub-id pub-id-type="pmid">30900486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2058738419838383</pub-id><pub-id pub-id-type="pmcid">PMC6431761</pub-id></mixed-citation></ref><ref id="psp413315-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="psp413315-cit-0002"><collab collab-type="authors">Diabetes Canada Clinical Practice Guidelines Expert Committee</collab>
, <string-name name-style="western"><given-names>V.</given-names><surname>Bril</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Breiner</surname></string-name>, <string-name name-style="western"><given-names>B. A.</given-names><surname>Perkins</surname></string-name>, and <string-name name-style="western"><given-names>D.</given-names><surname>Zochodne</surname></string-name>, &#8220;<article-title>Neuropathy</article-title>,&#8221; <source>Canadian Journal of Diabetes</source><volume>42</volume>, no. <issue>Suppl 1</issue> (<year>2018</year>): <fpage>S217</fpage>&#8211;<lpage>S221</lpage>.<pub-id pub-id-type="pmid">29650100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcjd.2017.10.028</pub-id></mixed-citation></ref><ref id="psp413315-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="psp413315-cit-0003"><string-name name-style="western"><given-names>R.</given-names><surname>Pop&#8208;Busui</surname></string-name>, <string-name name-style="western"><given-names>A. J. M.</given-names><surname>Boulton</surname></string-name>, <string-name name-style="western"><given-names>E. L.</given-names><surname>Feldman</surname></string-name>, et&#160;al., &#8220;<article-title>Diabetic Neuropathy: A Position Statement by the American Diabetes Association</article-title>,&#8221; <source>Diabetes Care</source><volume>40</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>136</fpage>&#8211;<lpage>154</lpage>.<pub-id pub-id-type="pmid">27999003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc16-2042</pub-id><pub-id pub-id-type="pmcid">PMC6977405</pub-id></mixed-citation></ref><ref id="psp413315-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="psp413315-cit-0004"><string-name name-style="western"><given-names>N.</given-names><surname>Attal</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Cruccu</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Baron</surname></string-name>, et&#160;al., &#8220;<article-title>EFNS Guidelines on the Pharmacological Treatment of Neuropathic Pain: 2010 Revision</article-title>,&#8221; <source>European Journal of Neurology</source><volume>17</volume>, no. <issue>9</issue> (<year>2010</year>): <fpage>1113&#8208;e88</fpage>.<pub-id pub-id-type="pmid">20402746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-1331.2010.02999.x</pub-id></mixed-citation></ref><ref id="psp413315-bib-0005"><label>5</label><mixed-citation publication-type="book" id="psp413315-cit-0005"><string-name name-style="western"><given-names>S. M.</given-names><surname>Dy</surname></string-name>, <string-name name-style="western"><given-names>W. L.</given-names><surname>Bennett</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Sharma</surname></string-name>, et&#160;al., <source>Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy [Internet]</source> (<publisher-name>Agency for Healthcare Research and Quality (US) (AHRQ Comparative Effectiveness Reviews)</publisher-name>), (<year>2017</year>), accessed December 20, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK442335/" ext-link-type="uri">http://www.ncbi.nlm.nih.gov/books/NBK442335/</ext-link>.<pub-id pub-id-type="pmid">28749633</pub-id></mixed-citation></ref><ref id="psp413315-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="psp413315-cit-0006"><string-name name-style="western"><given-names>S.</given-names><surname>Grond</surname></string-name> and <string-name name-style="western"><given-names>A.</given-names><surname>Sablotzki</surname></string-name>, &#8220;<article-title>Clinical Pharmacology of Tramadol</article-title>,&#8221; <source>Clinical Pharmacokinetics</source><volume>43</volume>, no. <issue>13</issue> (<year>2004</year>): <fpage>879</fpage>&#8211;<lpage>923</lpage>.<pub-id pub-id-type="pmid">15509185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200443130-00004</pub-id></mixed-citation></ref><ref id="psp413315-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="psp413315-cit-0007"><string-name name-style="western"><given-names>C.</given-names><surname>Gillen</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Haurand</surname></string-name>, <string-name name-style="western"><given-names>D. J.</given-names><surname>Kobelt</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Wnendt</surname></string-name>, &#8220;<article-title>Affinity, Potency and Efficacy of Tramadol and Its Metabolites at the Cloned Human Mu&#8208;Opioid Receptor</article-title>,&#8221; <source>Naunyn&#8208;Schmiedeberg's Archives of Pharmacology</source><volume>362</volume>, no. <issue>2</issue> (<year>2000</year>): <fpage>116</fpage>&#8211;<lpage>121</lpage>.<pub-id pub-id-type="pmid">10961373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s002100000266</pub-id></mixed-citation></ref><ref id="psp413315-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="psp413315-cit-0008"><string-name name-style="western"><given-names>L.</given-names><surname>Gong</surname></string-name>, <string-name name-style="western"><given-names>U. M.</given-names><surname>Stamer</surname></string-name>, <string-name name-style="western"><given-names>M. V.</given-names><surname>Tzvetkov</surname></string-name>, <string-name name-style="western"><given-names>R. B.</given-names><surname>Altman</surname></string-name>, and <string-name name-style="western"><given-names>T. E.</given-names><surname>Klein</surname></string-name>, &#8220;<article-title>PharmGKB Summary: Tramadol Pathway</article-title>,&#8221; <source>Pharmacogenetics and Genomics</source><volume>24</volume>, no. <issue>7</issue> (<year>2014</year>): <fpage>374</fpage>&#8211;<lpage>380</lpage>.<pub-id pub-id-type="pmid">24849324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/FPC.0000000000000057</pub-id><pub-id pub-id-type="pmcid">PMC4100774</pub-id></mixed-citation></ref><ref id="psp413315-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="psp413315-cit-0009"><string-name name-style="western"><given-names>O.</given-names><surname>Slanar</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Nobilis</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Kvetina</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Idle</surname></string-name>, and <string-name name-style="western"><given-names>F.</given-names><surname>Perl&#237;k</surname></string-name>, &#8220;<article-title>CYP2D6 Polymorphism, Tramadol Pharmacokinetics and Pupillary Response</article-title>,&#8221; <source>European Journal of Clinical Pharmacology</source><volume>62</volume>, no. <issue>1</issue> (<year>2006</year>): <fpage>75</fpage>&#8211;<lpage>76</lpage>. author reply 77&#8211;78.<pub-id pub-id-type="pmid">16283276</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00228-005-0039-1</pub-id></mixed-citation></ref><ref id="psp413315-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="psp413315-cit-0010"><string-name name-style="western"><given-names>W.</given-names><surname>Lintz</surname></string-name>, <string-name name-style="western"><given-names>H.</given-names><surname>Barth</surname></string-name>, <string-name name-style="western"><given-names>G.</given-names><surname>Osterloh</surname></string-name>, and <string-name name-style="western"><given-names>E.</given-names><surname>Schmidt&#8208;B&#246;thelt</surname></string-name>, &#8220;<article-title>Pharmacokinetics of Tramadol and Bioavailability of Enteral Tramadol Formulations. 3rd Communication: Suppositories</article-title>,&#8221; <source>Arzneimittel&#8208;Forschung</source><volume>48</volume>, no. <issue>9</issue> (<year>1998</year>): <fpage>889</fpage>&#8211;<lpage>899</lpage>.<pub-id pub-id-type="pmid">9793614</pub-id></mixed-citation></ref><ref id="psp413315-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="psp413315-cit-0011"><collab collab-type="authors">U.S. Food and Drug Administration (FDA)</collab>
, <article-title>&#8220;ULTRAM (Tramadol Hydrochloride) Tablets Full Prescribing Information [Internet],&#8221;</article-title> accessed August 28, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20281slr030,21123slr001_Ultram_lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20281slr030,21123slr001_Ultram_lbl.pdf</ext-link>.</mixed-citation></ref><ref id="psp413315-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="psp413315-cit-0012"><string-name name-style="western"><given-names>N. V.</given-names><surname>De Moraes</surname></string-name>, <string-name name-style="western"><given-names>G. R.</given-names><surname>Lauretti</surname></string-name>, and <string-name name-style="western"><given-names>V. L.</given-names><surname>Lanchote</surname></string-name>, &#8220;<article-title>Effects of Type 1 and Type 2 Diabetes on the Pharmacokinetics of Tramadol Enantiomers in Patients With Neuropathic Pain Phenotyped as Cytochrome P450 2D6 Extensive Metabolizers</article-title>,&#8221; <source>Journal of Pharmacy and Pharmacology</source><volume>66</volume>, no. <issue>9</issue> (<year>2014</year>): <fpage>1222</fpage>&#8211;<lpage>1230</lpage>.<pub-id pub-id-type="pmid">24717054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jphp.12255</pub-id></mixed-citation></ref><ref id="psp413315-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="psp413315-cit-0013"><string-name name-style="western"><given-names>Y.</given-names><surname>Harati</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gooch</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Swenson</surname></string-name>, et&#160;al., &#8220;<article-title>Double&#8208;Blind Randomized Trial of Tramadol for the Treatment of the Pain of Diabetic Neuropathy</article-title>,&#8221; <source>Neurology</source><volume>50</volume>, no. <issue>6</issue> (<year>1998</year>): <fpage>1842</fpage>&#8211;<lpage>1846</lpage>.<pub-id pub-id-type="pmid">9633738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.50.6.1842</pub-id></mixed-citation></ref><ref id="psp413315-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="psp413315-cit-0014"><string-name name-style="western"><given-names>Y.</given-names><surname>Harati</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Gooch</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Swenson</surname></string-name>, et&#160;al., &#8220;<article-title>Maintenance of the Long&#8208;Term Effectiveness of Tramadol in Treatment of the Pain of Diabetic Neuropathy</article-title>,&#8221; <source>Journal of Diabetes and Iits Complications</source><volume>14</volume>, no. <issue>2</issue> (<year>2000</year>): <fpage>65</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1056-8727(00)00060-x</pub-id><pub-id pub-id-type="pmid">10959067</pub-id></mixed-citation></ref><ref id="psp413315-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="psp413315-cit-0015"><string-name name-style="western"><given-names>H.</given-names><surname>Sun</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Saeedi</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Karuranga</surname></string-name>, et&#160;al., &#8220;<article-title>IDF Diabetes Atlas: Global, Regional and Country&#8208;Level Diabetes Prevalence Estimates for 2021 and Projections for 2045</article-title>,&#8221; <source>Diabetes Research and Clinical Practice</source><volume>183</volume> (<year>2022</year>): <elocation-id>109119</elocation-id>.<pub-id pub-id-type="pmid">34879977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2021.109119</pub-id><pub-id pub-id-type="pmcid">PMC11057359</pub-id></mixed-citation></ref><ref id="psp413315-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="psp413315-cit-0016"><string-name name-style="western"><given-names>N. V.</given-names><surname>De Moraes</surname></string-name>, <string-name name-style="western"><given-names>G. R.</given-names><surname>Lauretti</surname></string-name>, <string-name name-style="western"><given-names>M. N.</given-names><surname>Napolitano</surname></string-name>, <string-name name-style="western"><given-names>N. R.</given-names><surname>Santos</surname></string-name>, <string-name name-style="western"><given-names>A. L. P. C.</given-names><surname>Godoy</surname></string-name>, and <string-name name-style="western"><given-names>V. L.</given-names><surname>Lanchote</surname></string-name>, &#8220;<article-title>Enantioselective Analysis of Unbound Tramadol, O&#8208;Desmethyltramadol and N&#8208;Desmethyltramadol in Plasma by Ultrafiltration and LC&#8211;MS/MS: Application to Clinical Pharmacokinetics</article-title>,&#8221; <source>Journal of Chromatography B</source><volume>880</volume> (<year>2012</year>): <fpage>140</fpage>&#8211;<lpage>147</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jchromb.2011.11.033</pub-id><pub-id pub-id-type="pmid">22173007</pub-id></mixed-citation></ref><ref id="psp413315-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="psp413315-cit-0017"><string-name name-style="western"><given-names>L. A.</given-names><surname>Inker</surname></string-name>, <string-name name-style="western"><given-names>N. D.</given-names><surname>Eneanya</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Coresh</surname></string-name>, et&#160;al., &#8220;<article-title>New Creatinine&#8208; and Cystatin C&#8211;Based Equations to Estimate GFR Without Race</article-title>,&#8221; <source>New England Journal of Medicine</source><volume>385</volume>, no. <issue>19</issue> (<year>2021</year>): <fpage>1737</fpage>&#8211;<lpage>1749</lpage>.<pub-id pub-id-type="pmid">34554658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102953</pub-id><pub-id pub-id-type="pmcid">PMC8822996</pub-id></mixed-citation></ref><ref id="psp413315-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="psp413315-cit-0018"><string-name name-style="western"><given-names>B.</given-names><surname>Berger</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Chapuisat</surname></string-name>, <string-name name-style="western"><given-names>U.</given-names><surname>Duthaler</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Krahenbuhl</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Haschke</surname></string-name>, &#8220;<article-title>Cytochrome P450 Enzymes Involved in Metoprolol Metabolism and Use of Metoprolol as a CYP2D6 Phenotyping Probe Drug</article-title>,&#8221; <source>Frontiers in Pharmacology</source><volume>9</volume> (<year>2018</year>): <elocation-id>774</elocation-id>.<pub-id pub-id-type="pmid">30087611</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2018.00774</pub-id><pub-id pub-id-type="pmcid">PMC6066528</pub-id></mixed-citation></ref><ref id="psp413315-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="psp413315-cit-0019"><string-name name-style="western"><given-names>P. M.</given-names><surname>Cerqueira</surname></string-name>, <string-name name-style="western"><given-names>E. J.</given-names><surname>Cesarino</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Bertucci</surname></string-name>, <string-name name-style="western"><given-names>P. S.</given-names><surname>Bonato</surname></string-name>, and <string-name name-style="western"><given-names>V. L.</given-names><surname>Lanchote</surname></string-name>, &#8220;<article-title>Stereoselective Metabolism of Metoprolol: Enantioselectivity of Alpha&#8208;Hydroxymetoprolol in Plasma and Urine</article-title>,&#8221; <source>Chirality</source><volume>15</volume>, no. <issue>6</issue> (<year>2003</year>): <fpage>542</fpage>&#8211;<lpage>549</lpage>.<pub-id pub-id-type="pmid">12774293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/chir.10244</pub-id></mixed-citation></ref><ref id="psp413315-bib-0020"><label>20</label><mixed-citation publication-type="miscellaneous" id="psp413315-cit-0020"><article-title>&#8220;Tramadol|C16H25NO2|CID 33741 &#8208; PubChem [Internet].&#8221;</article-title> accessed September 24, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/Tramadol" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/Tramadol</ext-link>.</mixed-citation></ref><ref id="psp413315-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="psp413315-cit-0021"><article-title>&#8220;O&#8208;Desmethyltramadol|C15H23NO2|CID 9838803 &#8208; PubChem [Internet].&#8221;</article-title> accessed September 24, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/O-Desmethyltramadol" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/O&#8208;Desmethyltramadol</ext-link>.</mixed-citation></ref><ref id="psp413315-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="psp413315-cit-0022"><article-title>&#8220;N&#8208;Desmethyltramadol|C15H23NO2|CID 198555 &#8208; PubChem [Internet].&#8221;</article-title> accessed September 24, 2024, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/N-Desmethyltramadol" ext-link-type="uri">https://pubchem.ncbi.nlm.nih.gov/compound/N&#8208;Desmethyltramadol</ext-link>.</mixed-citation></ref><ref id="psp413315-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="psp413315-cit-0023"><string-name name-style="western"><given-names>R.</given-names><surname>Keizer</surname></string-name>, <string-name name-style="western"><given-names>M.</given-names><surname>Karlsson</surname></string-name>, and <string-name name-style="western"><given-names>A.</given-names><surname>Hooker</surname></string-name>, &#8220;<article-title>Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose</article-title>,&#8221; <source>CPT: Pharmacometrics &amp; Systems Pharmacology</source><volume>2</volume>, no. <issue>6</issue> (<year>2013</year>): <fpage>1</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/psp.2013.24</pub-id><pub-id pub-id-type="pmcid">PMC3697037</pub-id><pub-id pub-id-type="pmid">23836189</pub-id></mixed-citation></ref><ref id="psp413315-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="psp413315-cit-0024"><string-name name-style="western"><given-names>H.</given-names><surname>Zhou</surname></string-name>, &#8220;<article-title>Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles</article-title>,&#8221; <source>Journal of Clinical Pharmacology</source><volume>43</volume>, no. <issue>3</issue> (<year>2003</year>): <fpage>211</fpage>&#8211;<lpage>227</lpage>.<pub-id pub-id-type="pmid">12638389</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0091270002250613</pub-id></mixed-citation></ref><ref id="psp413315-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="psp413315-cit-0025"><string-name name-style="western"><given-names>M.</given-names><surname>Valle</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Garrido</surname></string-name>, <string-name name-style="western"><given-names>J. M.</given-names><surname>Pav&#243;n</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Calvo</surname></string-name>, and <string-name name-style="western"><given-names>I. F.</given-names><surname>Troc&#243;niz</surname></string-name>, &#8220;<article-title>Pharmacokinetic&#8208;Pharmacodynamic Modeling of the Antinociceptive Effects of Main Active Metabolites of Tramadol, (+)&#8208;O&#8208;Desmethyltramadol and (&#8722;)&#8208;O&#8208;Desmethyltramadol, in Rats</article-title>,&#8221; <source>Journal of Pharmacology and Experimental TherapeuticsJ</source><volume>293</volume>, no. <issue>2</issue> (<year>2000</year>): <fpage>646</fpage>&#8211;<lpage>653</lpage>.<pub-id pub-id-type="pmid">10773040</pub-id></mixed-citation></ref><ref id="psp413315-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="psp413315-cit-0026"><string-name name-style="western"><given-names>T.</given-names><surname>Long</surname></string-name>, <string-name name-style="western"><given-names>R.</given-names><surname>Cristofoletti</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>Cicali</surname></string-name>, et&#160;al., &#8220;<article-title>Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6&#8208;Mediated Drug&#8208;Drug Interactions on Tramadol and O&#8208;Desmethyltramadol Exposures via Allosteric and Competitive Inhibition</article-title>,&#8221; <source>Journal of Clinical Pharmacology</source><volume>62</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>76</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">34383318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.1951</pub-id><pub-id pub-id-type="pmcid">PMC9293201</pub-id></mixed-citation></ref><ref id="psp413315-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="psp413315-cit-0027"><string-name name-style="western"><given-names>H.</given-names><surname>T'jollyn</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Snoeys</surname></string-name>, <string-name name-style="western"><given-names>P.</given-names><surname>Colin</surname></string-name>, et&#160;al., &#8220;<article-title>Physiology&#8208;Based IVIVE Predictions of Tramadol From In&#160;Vitro Metabolism Data</article-title>,&#8221; <source>Pharmaceutical Research</source><volume>32</volume>, no. <issue>1</issue> (<year>2015</year>): <fpage>260</fpage>&#8211;<lpage>274</lpage>.<pub-id pub-id-type="pmid">25048637</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11095-014-1460-x</pub-id></mixed-citation></ref><ref id="psp413315-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="psp413315-cit-0028"><string-name name-style="western"><given-names>D. R.</given-names><surname>Mould</surname></string-name> and <string-name name-style="western"><given-names>R. N.</given-names><surname>Upton</surname></string-name>, &#8220;<article-title>Basic Concepts in Population Modeling, Simulation, and Model&#8208;Based Drug Development&#8208;Part 2: Introduction to Pharmacokinetic Modeling Methods</article-title>,&#8221; <source>CPT: Pharmacometrics &amp; Systems Pharmacology</source><volume>2</volume>, no. <issue>4</issue> (<year>2013</year>): <elocation-id>e38</elocation-id>.<pub-id pub-id-type="pmid">23887688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/psp.2013.14</pub-id><pub-id pub-id-type="pmcid">PMC3636497</pub-id></mixed-citation></ref><ref id="psp413315-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="psp413315-cit-0029"><string-name name-style="western"><given-names>R. H.</given-names><surname>Dworkin</surname></string-name>, <string-name name-style="western"><given-names>D. C.</given-names><surname>Turk</surname></string-name>, <string-name name-style="western"><given-names>K. W.</given-names><surname>Wyrwich</surname></string-name>, et&#160;al., &#8220;<article-title>Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations</article-title>,&#8221; <source>Journal of Pain</source><volume>9</volume>, no. <issue>2</issue> (<year>2008</year>): <fpage>105</fpage>&#8211;<lpage>121</lpage>.<pub-id pub-id-type="pmid">18055266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2007.09.005</pub-id></mixed-citation></ref><ref id="psp413315-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="psp413315-cit-0030"><string-name name-style="western"><given-names>F. G.</given-names><surname>Preston</surname></string-name>, <string-name name-style="western"><given-names>D. R.</given-names><surname>Riley</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Azmi</surname></string-name>, and <string-name name-style="western"><given-names>U.</given-names><surname>Alam</surname></string-name>, &#8220;<article-title>Painful Diabetic Peripheral Neuropathy: Practical Guidance and Challenges for Clinical Management</article-title>,&#8221; <source>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</source><volume>16</volume> (<year>2023</year>): <fpage>1595</fpage>&#8211;<lpage>1612</lpage>.<pub-id pub-id-type="pmid">37288250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DMSO.S370050</pub-id><pub-id pub-id-type="pmcid">PMC10243347</pub-id></mixed-citation></ref><ref id="psp413315-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="psp413315-cit-0031"><string-name name-style="western"><given-names>D.</given-names><surname>Ziegler</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Keller</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Maier</surname></string-name>, and <string-name name-style="western"><given-names>J.</given-names><surname>Pannek</surname></string-name>, &#8220;<article-title>Diabetic Neuropathy</article-title>,&#8221; <source>Experimental and Clinical Endocrinology &amp; Diabetes</source><volume>129</volume>, no. <issue>S 01</issue> (<year>2021</year>): <fpage>S70</fpage>&#8211;<lpage>S81</lpage>.<pub-id pub-id-type="pmid">34404106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/a-1284-6245</pub-id></mixed-citation></ref><ref id="psp413315-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="psp413315-cit-0032"><string-name name-style="western"><given-names>H.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>chen</surname></string-name>, <string-name name-style="western"><given-names>Y.</given-names><surname>Wang</surname></string-name>, <string-name name-style="western"><given-names>Y. n.</given-names><surname>Hou</surname></string-name>, and <string-name name-style="western"><given-names>Y. l.</given-names><surname>Wang</surname></string-name>, &#8220;<article-title>Stereoselectivity in Biliary Excretion of Trans Tramadol and Trans O&#8208;Demethyltramadol in Rats</article-title>,&#8221; <source>Yao Xue Xue Bao = Acta Pharmaceutica Sinica</source><volume>38</volume>, no. <issue>6</issue> (<year>2003</year>): <fpage>412</fpage>&#8211;<lpage>415</lpage>.<pub-id pub-id-type="pmid">14513798</pub-id></mixed-citation></ref><ref id="psp413315-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="psp413315-cit-0033"><string-name name-style="western"><given-names>Z.</given-names><surname>Esmaeili</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Mohammadi</surname></string-name>, <string-name name-style="western"><given-names>A.</given-names><surname>Nezami</surname></string-name>, et&#160;al., &#8220;<article-title>A Disposition Kinetic Study of Tramadol in Bile Duct Ligated Rats in Perfused Rat Liver Model</article-title>,&#8221; <source>Biomedicine &amp; Pharmacotherapy</source><volume>91</volume> (<year>2017</year>): <fpage>251</fpage>&#8211;<lpage>256</lpage>.<pub-id pub-id-type="pmid">28460228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2017.04.082</pub-id></mixed-citation></ref><ref id="psp413315-bib-0034"><label>34</label><mixed-citation publication-type="miscellaneous" id="psp413315-cit-0034"><string-name name-style="western"><given-names>I. V.</given-names><surname>Tetko</surname></string-name>, <article-title>&#8220;VCCLAB, Virtual Computational Chemistry Laboratory.&#8221;</article-title> Drug Discovery Today, (<year>2005</year>), <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://vcclab.org" ext-link-type="uri">https://vcclab.org</ext-link>.</mixed-citation></ref><ref id="psp413315-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="psp413315-cit-0035"><string-name name-style="western"><given-names>V.</given-names><surname>Subrahmanyam</surname></string-name>, <string-name name-style="western"><given-names>A. B.</given-names><surname>Renwick</surname></string-name>, <string-name name-style="western"><given-names>D. G.</given-names><surname>Walters</surname></string-name>, et&#160;al., &#8220;<article-title>Identification of Cytochrome P&#8208;450 Isoforms Responsible for Cis&#8208;Tramadol Metabolism in Human Liver Microsomes</article-title>,&#8221; <source>Drug Metabolism and Disposition</source><volume>29</volume>, no. <issue>8</issue> (<year>2001</year>): <fpage>1146</fpage>&#8211;<lpage>1155</lpage>.<pub-id pub-id-type="pmid">11454734</pub-id></mixed-citation></ref><ref id="psp413315-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="psp413315-cit-0036"><string-name name-style="western"><given-names>E.</given-names><surname>Garc&#237;a&#8208;Quetglas</surname></string-name>, <string-name name-style="western"><given-names>J. R.</given-names><surname>Azanza</surname></string-name>, <string-name name-style="western"><given-names>B.</given-names><surname>S&#225;daba</surname></string-name>, <string-name name-style="western"><given-names>M. J.</given-names><surname>Mu&#241;oz</surname></string-name>, <string-name name-style="western"><given-names>I.</given-names><surname>Gil</surname></string-name>, and <string-name name-style="western"><given-names>M. A.</given-names><surname>Campanero</surname></string-name>, &#8220;<article-title>Pharmacokinetics of Tramadol Enantiomers and Their Respective Phase I Metabolites in Relation to CYP2D6 Phenotype</article-title>,&#8221; <source>Pharmacological Research</source><volume>55</volume>, no. <issue>2</issue> (<year>2007</year>): <fpage>122</fpage>&#8211;<lpage>130</lpage>.<pub-id pub-id-type="pmid">17175164</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2006.11.003</pub-id></mixed-citation></ref><ref id="psp413315-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="psp413315-cit-0037"><string-name name-style="western"><given-names>W. N.</given-names><surname>Wu</surname></string-name>, <string-name name-style="western"><given-names>L. A.</given-names><surname>McKown</surname></string-name>, <string-name name-style="western"><given-names>A. D.</given-names><surname>Gauthier</surname></string-name>, <string-name name-style="western"><given-names>W. J.</given-names><surname>Jones</surname></string-name>, and <string-name name-style="western"><given-names>R. B.</given-names><surname>Raffa</surname></string-name>, &#8220;<article-title>Metabolism of the Analgesic Drug, Tramadol Hydrochloride, in Rat and Dog</article-title>,&#8221; <source>Xenobiotica</source><volume>31</volume>, no. <issue>7</issue> (<year>2001</year>): <fpage>423</fpage>&#8211;<lpage>441</lpage>.<pub-id pub-id-type="pmid">11531006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/00498250110057378</pub-id></mixed-citation></ref><ref id="psp413315-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="psp413315-cit-0038"><string-name name-style="western"><given-names>M.</given-names><surname>Dostalek</surname></string-name>, <string-name name-style="western"><given-names>F.</given-names><surname>Akhlaghi</surname></string-name>, and <string-name name-style="western"><given-names>M.</given-names><surname>Puzanovova</surname></string-name>, &#8220;<article-title>Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs</article-title>,&#8221; <source>Clinical Pharmacokinetics</source><volume>51</volume>, no. <issue>8</issue> (<year>2012</year>): <fpage>481</fpage>&#8211;<lpage>499</lpage>.<pub-id pub-id-type="pmid">22668340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11631900-000000000-00000</pub-id></mixed-citation></ref><ref id="psp413315-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="psp413315-cit-0039"><string-name name-style="western"><given-names>M. N.</given-names><surname>Celestin</surname></string-name> and <string-name name-style="western"><given-names>F. M.</given-names><surname>Musteata</surname></string-name>, &#8220;<article-title>Impact of Changes in Free Concentrations and Drug&#8208;Protein Binding on Drug Dosing Regimens in Special Populations and Disease States</article-title>,&#8221; <source>Journal of Pharmaceutical Sciences</source><volume>110</volume>, no. <issue>10</issue> (<year>2021</year>): <fpage>3331</fpage>&#8211;<lpage>3344</lpage>.<pub-id pub-id-type="pmid">34089711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2021.05.018</pub-id><pub-id pub-id-type="pmcid">PMC8458247</pub-id></mixed-citation></ref><ref id="psp413315-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="psp413315-cit-0040"><string-name name-style="western"><given-names>M. C.</given-names><surname>Chang</surname></string-name> and <string-name name-style="western"><given-names>S.</given-names><surname>Yang</surname></string-name>, &#8220;<article-title>Diabetic Peripheral Neuropathy Essentials: A Narrative Review</article-title>,&#8221; <source>Annals of Palliative Medicine</source><volume>12</volume>, no. <issue>2</issue> (<year>2023</year>): <fpage>39098</fpage>&#8211;<lpage>39398</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.21037/apm-22-693</pub-id><pub-id pub-id-type="pmid">36786097</pub-id></mixed-citation></ref><ref id="psp413315-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="psp413315-cit-0041"><string-name name-style="western"><given-names>S. B.</given-names><surname>Choi</surname></string-name>, <string-name name-style="western"><given-names>J. S.</given-names><surname>Jang</surname></string-name>, and <string-name name-style="western"><given-names>S.</given-names><surname>Park</surname></string-name>, &#8220;<article-title>Tramadol Enhances Hepatic Insulin Sensitivity via Enhancing Insulin Signaling Cascade in the Cerebral Cortex and Hypothalamus of 90% Pancreatectomized Rats</article-title>,&#8221; <source>Brain Research Bulletin</source><volume>67</volume>, no. <issue>1&#8211;2</issue> (<year>2005</year>): <fpage>77</fpage>&#8211;<lpage>86</lpage>.<pub-id pub-id-type="pmid">16140165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.brainresbull.2005.05.029</pub-id></mixed-citation></ref><ref id="psp413315-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="psp413315-cit-0042"><string-name name-style="western"><given-names>J. T.</given-names><surname>Cheng</surname></string-name>, <string-name name-style="western"><given-names>I. M.</given-names><surname>Liu</surname></string-name>, <string-name name-style="western"><given-names>T. C.</given-names><surname>Chi</surname></string-name>, <string-name name-style="western"><given-names>T. F.</given-names><surname>Tzeng</surname></string-name>, <string-name name-style="western"><given-names>F. H.</given-names><surname>Lu</surname></string-name>, and <string-name name-style="western"><given-names>C. J.</given-names><surname>Chang</surname></string-name>, &#8220;<article-title>Plasma Glucose&#8208;Lowering Effect of Tramadol in Streptozotocin&#8208;Induced Diabetic Rats</article-title>,&#8221; <source>Diabetes</source><volume>50</volume>, no. <issue>12</issue> (<year>2001</year>): <fpage>2815</fpage>&#8211;<lpage>2821</lpage>.<pub-id pub-id-type="pmid">11723065</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diabetes.50.12.2815</pub-id></mixed-citation></ref><ref id="psp413315-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="psp413315-cit-0043"><string-name name-style="western"><given-names>S.</given-names><surname>Derry</surname></string-name>, <string-name name-style="western"><given-names>R. F.</given-names><surname>Bell</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Straube</surname></string-name>, <string-name name-style="western"><given-names>P. J.</given-names><surname>Wiffen</surname></string-name>, <string-name name-style="western"><given-names>D.</given-names><surname>Aldington</surname></string-name>, and <string-name name-style="western"><given-names>R. A.</given-names><surname>Moore</surname></string-name>, &#8220;<article-title>Pregabalin for Neuropathic Pain in Adults</article-title>,&#8221; <source>Cochrane Database of Systematic Reviews</source><volume>1</volume>, no. <issue>1</issue> (<year>2019</year>): <elocation-id>CD007076</elocation-id>.<pub-id pub-id-type="pmid">30673120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD007076.pub3</pub-id><pub-id pub-id-type="pmcid">PMC6353204</pub-id></mixed-citation></ref><ref id="psp413315-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="psp413315-cit-0044"><string-name name-style="western"><given-names>O.</given-names><surname>Telli</surname></string-name> and <string-name name-style="western"><given-names>U.</given-names><surname>Cavlak</surname></string-name>, &#8220;<article-title>Measuring the Pain Threshold and Tolerance Using Electrical Stimulation in Patients With Type II Diabetes Mellitus</article-title>,&#8221; <source>Journal of Diabetic Complications</source><volume>20</volume>, no. <issue>5</issue> (<year>2006</year>): <fpage>308</fpage>&#8211;<lpage>316</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2005.07.004</pub-id><pub-id pub-id-type="pmid">16949518</pub-id></mixed-citation></ref><ref id="psp413315-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="psp413315-cit-0045"><string-name name-style="western"><given-names>N.</given-names><surname>Nanayakkara</surname></string-name>, <string-name name-style="western"><given-names>A. J.</given-names><surname>Curtis</surname></string-name>, <string-name name-style="western"><given-names>S.</given-names><surname>Heritier</surname></string-name>, et&#160;al., &#8220;<article-title>Impact of Age at Type 2 Diabetes Mellitus Diagnosis on Mortality and Vascular Complications: Systematic Review and Meta&#8208;Analyses</article-title>,&#8221; <source>Diabetologia</source><volume>64</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>275</fpage>&#8211;<lpage>287</lpage>.<pub-id pub-id-type="pmid">33313987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-020-05319-w</pub-id><pub-id pub-id-type="pmcid">PMC7801294</pub-id></mixed-citation></ref><ref id="psp413315-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="psp413315-cit-0046"><string-name name-style="western"><given-names>N. A.</given-names><surname>Calcutt</surname></string-name>, &#8220;<article-title>Diabetic Neuropathy and Neuropathic Pain: A (Con)fusion of Pathogenic Mechanisms?</article-title>,&#8221; <source>Pain</source><volume>161</volume>, no. <issue>Suppl 1</issue> (<year>2020</year>): <fpage>S65</fpage>&#8211;<lpage>S86</lpage>.<pub-id pub-id-type="pmid">32999525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/j.pain.0000000000001922</pub-id><pub-id pub-id-type="pmcid">PMC7521457</pub-id></mixed-citation></ref><ref id="psp413315-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="psp413315-cit-0047"><string-name name-style="western"><given-names>S.</given-names><surname>Kalra</surname></string-name> and <string-name name-style="western"><given-names>N.</given-names><surname>Raizada</surname></string-name>, &#8220;<article-title>Dyslipidemia in Diabetes</article-title>,&#8221; <source>Indian Heart Journal</source><volume>76</volume>, no. <issue>Suppl 1</issue> (<year>2024</year>): <fpage>S80</fpage>&#8211;<lpage>S82</lpage>.<pub-id pub-id-type="pmid">37956957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ihj.2023.11.002</pub-id><pub-id pub-id-type="pmcid">PMC11019325</pub-id></mixed-citation></ref><ref id="psp413315-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="psp413315-cit-0048"><string-name name-style="western"><given-names>C. T.</given-names><surname>Doughty</surname></string-name> and <string-name name-style="western"><given-names>M. P.</given-names><surname>Bowley</surname></string-name>, &#8220;<article-title>Entrapment Neuropathies of the Upper Extremity</article-title>,&#8221; <source>Medical Clinics of North America</source><volume>103</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>357</fpage>&#8211;<lpage>370</lpage>.<pub-id pub-id-type="pmid">30704687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mcna.2018.10.012</pub-id></mixed-citation></ref><ref id="psp413315-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="psp413315-cit-0049"><string-name name-style="western"><given-names>S.</given-names><surname>Nakhaee</surname></string-name>, <string-name name-style="western"><given-names>J.</given-names><surname>Brent</surname></string-name>, <string-name name-style="western"><given-names>C.</given-names><surname>Hoyte</surname></string-name>, et&#160;al., &#8220;<article-title>The Effect of Tramadol on Blood Glucose Concentrations: A Systematic Review</article-title>,&#8221; <source>Expert Review of Clinical Pharmacology</source><volume>13</volume>, no. <issue>5</issue> (<year>2020</year>): <fpage>531</fpage>&#8211;<lpage>543</lpage>.<pub-id pub-id-type="pmid">32295441</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/17512433.2020.1756773</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>